

10-23-00

A

Customer No. 20350
 TOWNSEND and TOWNSEND and CREW LLP
 Two Embarcadero Center, 8th Floor
 San Francisco, California 94111-3834
 (415) 576-0200

Attorney Docket No. 17682A-005100US

"Express Mail" Label No. EL008722715US

Date of Deposit: 10/19/00

ASSISTANT COMMISSIONER FOR PATENTS
 BOX PATENT APPLICATION
 Washington, D.C. 20231

Sir:

Transmitted herewith for filing under 37 CFR 1.171 is the

Reissue Patent Application of Patent No. 5,824,796
 continuation patent application of
 divisional patent application of
 continuation-in-part patent application of

Inventor(s)/Applicant Identifier: Charles R. Petrie, Rich B. Meyer, John C. Tabone and Gerald D. Hurst

For: CROSS-LINKING OLIGONUCLEOTIDES

Enclosed are:

26 page(s) of specification.
 10 page(s) of claims.
 7 page(s) of sequence listing.
 1 page of Abstract.
 3 sheet(s) of [] formal informal drawing(s).
 4 page(s) of Preliminary Remarks.
 2 page(s) of Cross-Reference under 37 § 1.82(e); and Statement under 37 CFR §§ 1.821 (f) & (g).
 A soft copy of U.S. Patent No. 5,824,796
 1 page of Reissue Application Assent by the Assignee and Offer to Surrender Patent with original Letters Patent enclosed
 1 page of verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27 is enclosed was filed in the prior application
 and small entity status is still proper and desired.
 2 page(s) of Assent by Assignee for Filing Reissue Application and Statement under 37 CFR § 3.73(b)
 12 page(s) of Combined Reissue Declarations of Charles R. Petrie, Rich B. Meyer and John C. Tabone Under 37 C.F.R. § 1.175(a) and Power of Attorney
 2 page(s) of Request to Transfer Drawings
 2 page(s) of Order for Title Report Under 37 C.F.R. § 1.71 with Exhibits A and B
 2 page(s) of Comments on References cited in Information Disclosure Statement with four references

jc853 us pro
 09/69/2013
 10/19/00

Claims after Entry of any Amendments, Less any Canceled Claims

(Col. 1)

(Col. 2)

SMALL ENTITY

OTHER THAN
SMALL ENTITY

FOR:	NO. FILED	NO. EXTRA
BASIC FEE		
TOTAL CLAIMS	42 - 20	= *22
INDEP. CLAIMS	12 - 3	= *9
[] MULTIPLE DEPENDENT CLAIM PRESENTED		

RATE	FEES
	\$345.00
x \$9.00 =	\$198.00
x \$39.00 =	\$351.00
+ \$130.00 =	
TOTAL	894.00

OR	RATE	FEES
OR		\$
OR	x \$18.00 =	\$
OR	x \$78.00 =	\$
OR	+ \$260.00 =	
OR	TOTAL	\$

* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

Please charge Deposit Account No. 20-1430 as follows:

Filing fee \$ 894.00
 Any additional fees associated with this paper or during the pendency of this application.
 The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b)

A check for \$ _____ is enclosed.
 2 extra copies of this sheet are enclosed.

Respectfully submitted,

TOWNSEND and TOWNSEND and CREW LLP

William B. Kezer
 Reg No.: 37,369
 Attorneys for Applicant

Telephone:
 (415) 576-0200

Faxsimile:
 (415) 576-0300

"Express Mail" Label No. **EL008722715US**
Date of Deposit 10/19/00

PATENT
17682A-005100

jc853 U.S. PTO
09/693213
10/19/00



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:

Petrie et al.

Patent No.: 5,824,796

Issued: October 20, 1998

Application No.: Not Yet Assigned

Filed: Herewith

For: **CROSS-LINKING
OLIGONUCLEOTIDES**

**REISSUE APPLICATION ASSENT BY
THE ASSIGNEE AND OFFER TO
SURRENDER PATENT**

BOX REISSUE APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The undersigned assignee, Epoch Biosciences, Inc., of the accompanying reissue application for the reissue of letters patent entitled "CROSS LINKING OF OLIGONUCLEOTIDES," U.S. Patent No. 5,824,796, granted October 20, 1998, of which Epoch Biosciences, Inc. is the sole owner by assignment, and on whose behalf and with whose assent the accompanying reissue application is made, hereby offers to surrender said Letters Patent. An order for title report is enclosed herewith.

EPOCH BIOSCIENCES, INC.

Date: 16 Oct 2000

By: W.G. Gerber

Name: William G. Gerber

Title: CEO

SF1142430

jc853 u.s. pro
09/693213
09/19/00



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:

Petrie et al.

Patent No.: 5,824,796

Issued: October 20, 1998

Application No.: Not Yet Assigned

Filed: Herewith

For: **CROSS-LINKING
OLIGONUCLEOTIDES**

**ASSENT BY ASSIGNEE FOR FILING
REISSUE APPLICATION, AND
STATEMENT UNDER 37 C.F.R. § 3.73(b)**

BOX REISSUE APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Epoch Biosciences, Inc. is the assignee of one hundred percent (100%) interest in the above-identified original United States patent. Epoch Biosciences, Inc. hereby assents to the accompanying application for reissue.

Epoch Biosciences, Inc.

By: Wossler

Date: 16 OCT 2000

SF1142727

STATEMENT UNDER 37 C.F.R. § 3.73(b)

Epoch Biosciences, Inc., a Delaware corporation, certifies that it is assignee of the entire right, title, and interest in the above-identified patent application by virtue of an assignment from the inventors to Microprobe Corporation (now Epoch Biosciences, Inc.) recorded in the United States Patent and Trademark Office on October 26, 1988 at Reel 4963, Frame 220 for parent application Serial No. 250,474 and on July 24, 1989 at Reel 5162, Frame 48 for parent application Serial No. 353,857.

The undersigned William Gerber, hereby declares that he is authorized to sign this statement on behalf of the assignee, and that all statements made herein of his own knowledge are true, and all statements made on information and belief are believed to be true, and that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Epoch Biosciences, Inc.

By: W. Gerber

Date: 16 OCT 2000

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(c)) - SMALL BUSINESS CONCERN

Applicant or Patentee: Charles R. Petrie, Rich B. Meyers, John C. Tabone and Gerald D. Hurst
 Application or Patent No.: 5,824,796
 Filed or Issued: October 20, 1998
 Title: CROSS-LINKING OLIGONUCLEOTIDES

I hereby declare that I am:

the owner of the small business concern identified below:
 an official of the small business concern empowered to act on behalf of the concern identified below.

Name of Small Business Concern: Epoch Biosciences, Inc.
 Address of Small Business Concern: 12277 134th Court NE Suite 110
Redmond, WA 98052

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled **CROSS-LINKING OLIGONUCLEOTIDES** by inventor(s) **Charles R. Petrie, Rich B. Meyer, John C. Tabone and Gerald D. Hurst** described in:

the specification filed herewith;
 Application No. _____, filed _____;
 Patent No. _____, issued _____.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern that would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Name: _____
 Address: _____

Individual Small Business Concern Nonprofit Organization

Name: _____
 Address: _____

Individual Small Business Concern Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing: William G. Gerber, M.D.
 Title of Person if Other than Owner: Chief Executive Officer
 Address of Person Signing: 12277 134th Court NE Suite 110
Redmond, WA 98052

Signature W.G. Gerber Date 16 OCT 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Petrie et al.

Patent No.: 5,824,796

Issued: October 20, 1998

Application No.: Not Yet Assigned

Filed: Herewith

For: CROSS-LINKING
OLIGONUCLEOTIDES

PRELIMINARY REMARKS

Commissioner of Patents and Trademarks
Box Reissue
Washington, D.C. 20231

PRELIMINARY REMARKS

Dear Sir:

Prior to examination of the above-referenced application for Reissue, please enter and consider the following remarks.

Claims 1, 8, 10 and 13 have been amended to correct minor typographical errors.

Claims 16-44 are new. Accordingly, Claims 1-15 are pending in this reissue application.

In each of claims 1, 8, 10 and 13, the work "phtalimido" has been replaced by the conventional spelling of -- phthalimido -- .

Claims 16-24 are directed to compounds disclosed in the specification at columns 9 and 10. Particularly at column 10, lines 27-47, wherein the claimed compounds are described in the context of intermediates in the preparation of the originally claimed pyrazolo[3,4-d]pyrimidines. More particularly, with reference to formula (I), the specification

recites “[l]inker arms may include alkylene groups of 1 to 12 carbon atoms, alkenylene groups of 2 to 12 carbon atoms and 1 or 2 olefinic bonds, alkynylene groups of 2 to 12 carbon atoms and 1 or 2 acetylenic bonds, or such groups substituted at a terminal point with nucleophilic groups such as oxy, thio, amino or chemically blocked derivatives thereof...”

Claims 21 and 22 are directed to compounds having a pyrimidine base moiety and modified as noted above for the pyrazolo[3,4-d]pyrimidines (see, for example, Schemes 1 and 2, columns 7 and 8). The specification at column 7, lines 22-40, notes that the invention is directed to two classes of compounds that have demonstrated particular usefulness upon incorporation into oligonucleotides. The first class of compounds are the pyrimidine derivatives, the preparation of which is shown in Schemes 1 and 2. A comparison of the side chain components finds that these schemes illustrate the incorporation of alkynylene, alkenylene and alkylene chains which terminate in Y', a group useful for the attachment of A'. Accordingly, Applicants have added claims 21 and 22 directed to these intermediates, but reducing the scope in view of, for example, Robins et al., Can. J. Chem. 60:554 (1982) and J. Org. Chem. 48:1854 (1983), and Ward et al., U.S. Pat. No. 4,711,955 references of record in the parent application.

Claims 23-28 are directed to oligonucleotides incorporating the modified bases provided in claims 16-22. Support for these claims can be found in those areas provided above for the nucleotide units and in the statement beginning at column 7, line 22, that “[t]wo classes of modified 2'deoxynucleosides have demonstrated particular usefulness in the present invention *for incorporation into oligonucleotides ...*” (emphasis added).

New claims 29-30 and 31-32 are dependent on claims 10 and 13, respectively and recite the limitations wherein the reporter group is selected from ^3H , ^{125}I , ^{35}S , ^{14}C and ^{32}P (see column 14, lines 1-4), and more preferably, ^3H .

New claims 33-44 are directed to the compounds and oligonucleotides having bases and labels as provided above, but having linking groups including the unsaturated linking groups (e.g., alkenylene and alkynylene). More particularly, claim 33 recites a labeled oligonucleotide having at least one pyrazolo[3,4-d]pyrimidine nucleotide unit with a reporter group (A) attached via a linker (W). Support for this group of embodiments can be found at column 9, lines 28-60, wherein W is a chemical linker arm (see column 9, line 51, and column

Application No.:
Page 3

10, lines 33-35) and A is a reporter group (see column 9, lines 53-55). The portion designated in the specification as $-(X)_n-$ is not depicted in the claimed formula as the subscript n is 0 in this group of embodiments. Claims 34 and 35 recites certain radiolabels (see column 14, lines 1-4).

In a related group of embodiments, claims 36-38 recite similar labeled oligonucleotides in which the label is pendent to a pyrimidine base, e.g., as depicted in column 7. In order to be consistent with claims 33-35, the pendent linker and label have been depicted as -W-A, in which W and A have the same definitions as provided above. Applicants believe the equivalent scope sought for linking group and reporter group in this series of claims would be apparent to one of skill in the art upon viewing the general structure, Schemes 1 and 2, and the recitation that two classes of modified bases have demonstrated usefulness in the present invention.

Claims 39-41 and 42-44 recite groups of compounds (pyrazolo[3,4-d]pyrimidines and pyrimidines, respectively) having attached reporter groups. More particularly, these claims are directed to the monomers used in the oligonucleotides provided in claims 33-38. Support in the specification can be found as outlined above.

Applicants believe no new matter is presented in any portion of the requested amendments.

Concerning the sequence listings contained in the specification, the Office's attention is respectfully directed to the enclosed Cross-Reference under 37 C.F.R. § 1.821(e); and Statement under 37 C.F.R. §§ 1.821 (f) and (g).

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

Application No.:

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

Will B. Kizer
William B. Kizer

William B. Kezer
Reg. No. 37,369

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
WBK
SF 1144542 v1

SF 1144542 v1

WHAT IS CLAIMED IS:

1 1. (Amended) An oligonucleotide having at least one nucleotide of
2 the formula

$$R_1-B-(CH_2)_q-(Y)_r-(CH_2)_m-A'$$

4 wherein

5 R₁ is a 1-(β -D-ribofuranosyl) or 1-(β -D-2-deoxyribofuranosyl) group which is
6 optionally substituted on one or more of its hydroxyl functions with a Z group,
7 wherein Z independently is methyl or a phosphate, thiophosphate, alkylphosphate
8 or alkanephosphonate group;

9 B is a heterocyclic base selected from purine and pyrazolo[3,4-d]pyrimidine groups
10 wherein the $(CH_2)_q$ group is attached to the 7-position or 8 position of the purine
11 and 3-position of the pyrazolo[3,4-d]pyrimidine groups and the R_1 group is
12 attached to the 9-position of the purine and to the 1-position of the pyrazolo[3,4-
13 d]pyrimidine groups;

Y is a functional linking group selected from a group consisting of -O-, -S-, -NR'-, -NH-CO-, trifluoroacetamido and [phtalimido] phtalimido groups where R' is H or C₁₋₆ alkyl, and at least one of the (CH₂)_m and (CH₂)_q groups is directly linked to the -O-, -S-, -NR'-, NH-CO-, trifluoroacetamido and [phtalimido] phtalimido groups and the other of said (CH₂)_m and (CH₂)_q groups is linked to the heterocyclic base with a carbon to carbon bond;

20 m is 1 to 8, inclusive;

21 q is 0 to 8, inclusive;

22 r is 0 or 1; and

23 A' is a group selected from chloro, bromo, iodo, $\text{SO}_2\text{R}''$, $\text{S}^+\text{R}''\text{R}'''$ and a radical
24 which activates the carbon to which it is attached for nucleophilic substitution,
25 where each of R'' and R''' is independently C_{1-6} alkyl or aryl or R'' and R'''
26 together form a C_{1-6} alkylene bridge.

1 2. An oligonucleotide according to claim 1 wherein B is selected from
2 adenine-8-yl, guanine-8-yl, 4-aminopyrazolo[3,4-d]pyrimidin-3-yl, and 4-amino-6-
3 oxopyrazolo[3,4-d]pyrimidin-3-yl groups.

1 3. An oligonucleotide according to claim 1 wherein m is 1, 2 or 3; q is
2 2, 3, or 4; and r is 1.


1 **4.** An oligonucleotide according to claim **1** wherein the R₁ group is 1-
2 (β-D-ribofuranosyl).

1 **5.** An oligonucleotide according to claim **1** wherein the R₁ group is 1-
2 (β-D-2-deoxyribofuranosyl).

1 **6.** An oligonucleotide according to claim **1** wherein the R₁ group is 1-
2 (β-D-2-O-methyl-ribofuranosyl).

1 **7.** An oligonucleotide according to claim **1** wherein the group
2 -(CH₂)_q-(Y)_r-(CH₂)_m-A' is 3-iodoacetamidopropyl, 3-(4-bromobutyramido)propyl, 4-
3 iodoacetamidobutyl, or 4-(4-bromobutyramido)butyl.

1 **8.** (Amended) A compound of the formula /



1 where R₁ is H, or a 1-(β-D-ribofuranosyl) or 1-(β-D-deoxyribofuranosyl) group which
2 is optionally substituted on one or more of its hydroxyl functions with a Z group
3 wherein Z independently is methyl or a phosphate, thiophosphate, alkylphosphate
4 or alkanephosphonate group, or a reactive precursor of said phosphate,
5 thiophosphate, alkylphosphate or alkanephosphonate group which precursor is
6 suitable for internucleotide bond formation;


7 R₃ is (CH₂)_q-(Y)-R₂ where A" is a group selected from chloro, bromo, iodo,
8 SO₂R", S⁺R"R"" and a radical which activates the carbon to which it is attached
9 for nucleophilic substitution, where each of R" and R"" is independently C₁₋₆
10 alkyl or aryl or R" and R"" together form a C₁₋₆ alkylene bridge, or A" is an
11 intercalator group, a metal ion chelator or a reporter group;

12 Y is a functional linking group selected from a group consisting of -O-, -S-, -NR'-,
13 -NH-CO-, trifluoroacetamido and [phtalimido] phtalimido groups where R' is H
14 or C₁₋₆ alkyl, and at least one of the (CH₂)_m and (CH₂)_q groups is directly linked to
15 said -O-, -S-, -NR'-, NH-CO-, trifluoroacetamido and [phtalimido] phtalimido
16 groups and the other of said (CH₂)_m and (CH₂)_q groups is linked to the heterocyclic
17 base with a carbon to carbon bond;

20 each of m and q is independently 0 to 8, inclusive; r is 0 or 1 provided that when A" is
21 a group selected from chloro, bromo, iodo, $\text{SO}_2\text{R}''$, $\text{S}^+\text{R}''\text{R}'''$ and a radical which
22 activates the carbon to which it is attached for nucleophilic substitution, then m is
23 not 0;
24 each of R_4 and R_6 is independently H, OR, SR, NHOR, NH_2 , or $\text{NH}(\text{CH}_2)_t\text{NH}_2$ where
25 R is H or C_{1-6} alkyl and t is an integer from 0 to 12.

1 9. A compound in accordance with claim 8 where each of R_4 and R_6
2 is independently selected from a group consisting of H, OH and NH_2 .

1 10. A compound of the formula



2 3 where R_1 is H, or a 1-(β -D-ribofuranosyl) or 1-(β -D-deoxyribofuranosyl) group which
4 is optionally substituted on one or more of its hydroxyl functions with a Z group
5 wherein Z independently is methyl or a phosphate, thiophosphate, alkylphosphate
6 or alkanephosphonate group, or a reactive precursor of said phosphate,
7 thiophosphate, alkylphosphate or alkanephosphonate group which precursor is
8 suitable for internucleotide bond formation;

9 R₃ is $(\text{CH}_2)_q-(\text{Y})_r-(\text{CH}_2)_m-\text{A}''$ where A" is a reporter group;
10 Y is a functional linking group selected from a group consisting of -O-, -S-, -NR'-,
11 -NH-CO-, trifluoroacetamido and [phthalimido] phthalimido groups where R' is H
12 or C_{1-6} alkyl, and at least one of the $(\text{CH}_2)_m$ and $(\text{CH}_2)_q$ groups is directly linked to
13 said -O-, -S-, -NR'-, NH-CO-, trifluoroacetamido and [phthalimido] phthalimido
14 groups and the other of said $(\text{CH}_2)_m$ and $(\text{CH}_2)_q$ groups is linked to the heterocyclic
15 base with a carbon to carbon bond;
16 each of m and q is independently 0 to 8, inclusive; r is 0 or 1, and
17 each of R_4 and R_6 is independently H, OR, SR, NHOR, NH_2 , or $\text{NH}(\text{CH}_2)_t\text{NH}_2$ where
18 R is H or C_{1-6} alkyl and t is an integer from 0 to 12.

1 11. A compound in accordance with claim 10 where each of R_4 and R_6
2 is independently selected from a group consisting of H, OH and NH_2 .

1 **12.** A compound in accordance with claim **11** where the reporter group
2 is biotin or 2,4-dinitrobenzene.

1 **13.** An oligonucleotide having at least one nucleotide of the formula



2 where R₁ is a 1-(β -D-ribofuranosyl) or 1-(β -D-2-deoxyribofuranosyl) group which is
3 optionally substituted on one or more of its hydroxyl functions with a Z group
4 wherein Z independently is methyl or a phosphate, thiophosphate, alkylphosphate
5 or alkanephosphonate group;

6 R₃ is (CH₂)_q-(Y)_r-(CH₂)_m-A and A is a reporter group;

7 Y is a functional linking group selected from a group consisting of -O-, -S-, -NR'-,
8 -NH-CO-, trifluoroacetamido and [phtalimido] phtalimido groups where R' is H
9 or C₁₋₆ alkyl, and at least one of the (CH₂)_m and (CH₂)_q groups is directly linked to
10 said -O-, -S-, -NR'-, NH-CO-, trifluoroacetamido and [phtalimido] phtalimido
11 groups and the other of said (CH₂)_m and (CH₂)_q groups is linked to the heterocyclic
12 base with a carbon to carbon bond;


13 each of m and q is independently 0 to 8, inclusive; r is 0 or 1, and

14 each of R₄ and R₆ is independently H, OR, SR, NHOR, NH₂, or NH(CH₂)_tNH₂ where
15 R is H or C₁₋₆alkyl and t is an integer from 0 to 12.

1 **14.** An oligonucleotide in accordance with claim **13** where each of R₄
2 and R₆ is independently selected from a group consisting of H, OH and NH₂.

1 **15.** An oligonucleotide in accordance with claim **14** where the reporter
2 group is biotin or 2,4-dinitrobenzene.

1 **16.** (New) A compound having the formula



3 wherein R₁ is H, or a 1-(β -D-ribofuranosyl) or 1-(β -D-2-deoxyribofuranosyl) group
4 which is optionally substituted on one or more of its hydroxyl functions with a Z
5 group wherein Z independently is methyl or a phosphate, thiophosphate,
6 alkylphosphate or alkanephosphonate group which precursor is suitable for
7 internucleotide bond formation;

8 R₃ is -W-X, wherein W is a chemical linker arm selected from the group consisting of
9 C₁₋₁₂ alkylene, C₂₋₁₂ alkenylene and C₂₋₁₂ alkynylene, and X is selected from the
10 group consisting of OH, SH, NH₂ and chemically blocked derivatives thereof;
11 each of R₄ and R₆ is independently H, OR, SR, NHOR, NH₂, or NH(CH₂)_tNH₂ where
12 R is H or C₁₋₆alkyl and t is an integer from 0 to 12
13 with the proviso that when W is -CH₂CH₂-, then X is other than NH₂.


1 **17.** (New) A compound of claim 16, wherein W is C₁₋₁₂ alkylene and
2 X is selected from the group consisting of OH, NH₂ and chemically blocked derivatives
3 thereof.

1 **18.** (New) A compound of claim 16, wherein W is C₂₋₁₂ alkynylene
2 and X is selected from the group consisting of OH, NH₂ and chemically blocked
3 derivatives thereof.

1 **19.** (New) A compound of claim 17, wherein W is pentyl and X is
2 NH-trityl.

1 **20.** (New) A compound of claim 16, wherein R₄ is NH₂ or OH and R₆
2 is H or NH₂

1 **21.** (New) A compound having the formula




3 wherein R₁ is a 1-(β -D-ribofuranosyl) or 1-(β -D-2-deoxyribofuranosyl) group which
4 is optionally substituted on one or more of its hydroxyl functions with a Z group
5 wherein Z independently is methyl or a phosphate, thiophosphate, alkylphosphate
6 or alkanephosphonate group which precursor is suitable for internucleotide bond
7 formation;

8 W is a chemical linker arm selected from the group consisting of C₂₋₁₂ alkynylene,
9 and Y' is selected from the group consisting of OH, SH and chemically blocked
10 derivatives thereof.

1 22. (New) A compound of claim 21, wherein Y' is selected from the
2 group consisting of OH and chemically blocked derivatives thereof.

1 23. (New) An oligonucleotide comprising at least one nucleotide unit
2 of the formula



3 4 wherein R₁ is a 1-(β-D-ribofuranosyl) or 1-(β-D-2-deoxyribofuranosyl) group which
5 is optionally substituted on one or more of its hydroxyl functions with a Z group
6 wherein Z independently is methyl or a phosphate, thiophosphate, alkylphosphate
7 or alkanephosphonate group which precursor is suitable for internucleotide bond
8 formation;

9 10 R₃ is -W-X, wherein W is a chemical linker arm selected from the group consisting of
11 C₁₋₁₂ alkylene, C₂₋₁₂ alkenylene and C₂₋₁₂ alkynylene, and X is selected from the
12 group consisting of OH, SH, NH₂ and chemically blocked derivatives thereof;
13 each of R₄ and R₆ is independently H, OR, SR, NHOR, NH₂, or NH(CH₂)_tNH₂ where
14 R is H or C₁₋₆alkyl and t is an integer from 0 to 12.


1 24. (New) An oligonucleotide of claim 23, wherein W is C₁₋₁₂
2 alkylene and X is selected from the group consisting of OH, NH₂ and chemically blocked
3 derivatives thereof.

1 25. (New) An oligonucleotide of claim 23, wherein W is C₂₋₁₂
2 alkynylene and X is selected from the group consisting of OH, NH₂ and chemically
3 blocked derivatives thereof.

1 26. (New) An oligonucleotide of claim 24, wherein W is pentyl and X
2 is NH-trityl.

1 27. (New) An oligonucleotide comprising at least one nucleotide unit ✓

2 of the formula



4 wherein R₁ is a 1-(β -D-ribofuranosyl) or 1-(β -D-2-deoxyribofuranosyl) group which
5 is optionally substituted on one or more of its hydroxyl functions with a Z group
6 wherein Z independently is methyl or a phosphate, thiophosphate, alkylphosphate
7 or alkanephosphonate group which precursor is suitable for internucleotide bond
8 formation;

9 W is a chemical linker arm selected from the group consisting of C₂-₁₂ alkynylene,
10 and Y' is selected from the group consisting of OH, SH and chemically blocked
11 derivatives thereof.

1 28. (New) An oligonucleotide of claim 27, wherein Y' is selected
2 from the group consisting of OH and chemically blocked derivatives thereof.

1 29. (New) A compound of claim 10, wherein the reporter group is
2 selected from the group consisting of ³H, ¹²⁵I, ³⁵S, ¹⁴C and ³²P.


1 30. (New) A compound of claim 10, wherein the reporter group is ³H.

1 31. (New) An oligonucleotide of claim 13, wherein the reporter group
2 is selected from the group consisting of ³H, ¹²⁵I, ³⁵S, ¹⁴C and ³²P.

1 32. (New) An oligonucleotide of claim 13, wherein the reporter group
2 is ³H.

1 33. (New) A labeled oligonucleotide comprising at least one ✓

2 nucleotide unit of the formula




4 wherein R₁ is a 1-(β -D-ribofuranosyl) or 1-(β -D-2-deoxyribofuranosyl) group which
5 is optionally substituted on one or more of its hydroxyl functions with a Z group
6 wherein Z independently is methyl or a phosphate, thiophosphate, alkylphosphate
7 or alkanephosphonate group which precursor is suitable for internucleotide bond
8 formation;

9 R₃ is -W-A, wherein W is a chemical linker arm selected from the group consisting of
10 C₁₋₁₂ alkylene, C₂₋₁₂ alkenylene and C₂₋₁₂ alkynylene, and A is a reporter group;
11 and
12 each of R₄ and R₆ is independently H, OR, SR, NHOR, NH₂, or NH(CH₂)_tNH₂ where
13 R is H or C₁₋₆alkyl and t is an integer from 0 to 12.

1 34. (New) A labeled oligonucleotide of claim 33, wherein said
2 reporter group is selected from the group consisting of ³H, ¹²⁵I, ³⁵S, ¹⁴C and ³²P.

1 35. (New) A labeled oligonucleotide of claim 33, wherein said
2 reporter group is ³H.

1 36. (New) A labeled oligonucleotide comprising at least one
2 nucleotide unit of the formula




4 wherein R₁ is a 1-(β -D-ribofuranosyl) or 1-(β -D-2-deoxyribofuranosyl) group which
5 is optionally substituted on one or more of its hydroxyl functions with a Z group
6 wherein Z independently is methyl or a phosphate, thiophosphate, alkylphosphate
7 or alkanephosphonate group which precursor is suitable for internucleotide bond
8 formation;

9 W is a chemical linker arm selected from the group consisting of C₂₋₁₂ alkynylene;
10 and
11 A is a reporter group.

1 37. (New) A labeled oligonucleotide of claim 36, wherein said
2 reporter group is selected from the group consisting of ³H, ¹²⁵I, ³⁵S, ¹⁴C and ³²P.

1 **38.** (New) A labeled oligonucleotide of claim 36, wherein said
2 reporter group is ^3H .

1 **39.** (New) A compound having the formula



3 wherein R_1 is H, or a 1-(β -D-ribofuranosyl) or 1-(β -D-2-deoxyribofuranosyl) group
4 which is optionally substituted on one or more of its hydroxyl functions with a Z
5 group wherein Z independently is methyl or a phosphate, thiophosphate,
6 alkylphosphate or alkanephosphonate group which precursor is suitable for
7 internucleotide bond formation;


8 R_3 is $-\text{W}-\text{A}$, wherein W is a chemical linker arm selected from the group consisting of
9 C_{1-12} alkylene, C_{2-12} alkenylene and C_{2-12} alkynylene, and A is a reporter group;
10 and

11 each of R_4 and R_6 is independently H, OR, SR, NHOR, NH_2 , or $\text{NH}(\text{CH}_2)_t\text{NH}_2$ where
12 R is H or C_{1-6} alkyl and t is an integer from 0 to 12.

1 **40.** (New) A compound of claim 39, wherein said reporter group is
2 selected from the group consisting of ^3H , ^{125}I , ^{35}S , ^{14}C and ^{32}P .

1 **41.** (New) A compound of claim 39, wherein said reporter group is ^3H .

1 **42.** (New) A compound having the formula



3 wherein R_1 is a 1-(β -D-ribofuranosyl) or 1-(β -D-2-deoxyribofuranosyl) group which
4 is optionally substituted on one or more of its hydroxyl functions with a Z group
5 wherein Z independently is methyl or a phosphate, thiophosphate, alkylphosphate
6 or alkanephosphonate group which precursor is suitable for internucleotide bond
7 formation;

8 W is a chemical linker arm selected from the group consisting of C₂₋₁₂ alkynylene;
9 and
10 A is a reporter group.

1 **43.** (New) A compound of claim 42, wherein said reporter group is
2 selected from the group consisting of ³H, ¹²⁵I, ³⁵S, ¹⁴C and ³²P.

1 **44.** (New) A compound of claim 42, wherein said reporter group is ³H.

SF 1129390 v1

Express Mail Label No.
EL008722715US

[54] CROSS-LINKING OLIGONUCLEOTIDES

[75] Inventors: Charles R. Petrie; Rich B. Meyer,
both of Woodinville; John C. Tabone,
Bothell, all of Wash.; Gerald D. Hurst,
Iowa City, Iowa

[73] Assignee: EPOCH Pharmaceuticals, Inc.
Bothell, Wash.

[21] Appl. No.: 334,490

[22] Filed: Nov. 4, 1994

Related U.S. Application Data

[63] Continuation of Ser. No. 49,807, Apr. 20, 1993, abandoned,
which is a continuation of Ser. No. 353,857, May 18, 1989,
abandoned, which is a continuation-in-part of Ser. No.
250,474, Sep. 28, 1988, abandoned.

[51] Int. Cl.⁴ C07H 19/04; C07H 21/00;
C07H 21/02; C07H 21/04

[52] U.S. Cl. 536/26.7; 536/24.5

[58] Field of Search 536/26.1, 26.12,
536/26.13, 26.14, 26.8, 27.6, 27.81, 28.5,
28.54, 26.7, 24.5

[56] References Cited

U.S. PATENT DOCUMENTS

3,598,807	8/1971	Nakayama et al.
3,962,211	6/1976	Townsend et al.
4,123,610	10/1978	Summerston et al.
4,582,789	4/1986	Sheidorn et al.
4,599,303	7/1986	Yabasaki et al.
4,711,955	12/1987	Ward et al.
4,786,062	8/1988	Diamond et al.
4,795,700	1/1989	Dervan et al.
4,837,311	6/1989	Tam et al.
5,176,996	1/1993	Hogan et al.

FOREIGN PATENT DOCUMENTS

0021293	1/1981	European Pat. Off.
0198207	10/1986	European Pat. Off.
0227459	7/1987	European Pat. Off.
0242264	10/1987	European Pat. Off.
0259186	3/1988	European Pat. Off.
0266099	5/1988	European Pat. Off.
0267996	5/1988	European Pat. Off.
0375406	6/1990	European Pat. Off.
3310337	9/1984	Germany.
6109797	11/1984	Japan.
84/03285	8/1984	WIPO
W08502628	6/1985	WIPO
W08503075	7/1985	WIPO
86/02929	5/1986	WIPO
86/04416	8/1986	WIPO
W08707611	12/1987	WIPO
88/10264	12/1988	WIPO
90/14353	11/1990	WIPO
90/15834	12/1990	WIPO
91/18997	12/1991	WIPO
92/20698	11/1992	WIPO
93/03736	3/1993	WIPO

OTHER PUBLICATIONS

Hobbs, Frank W. Jr. *Org. Chem.*, (1989) 54:3420-3422.
Umlauf, Scott W. et al. *J. of Bio. Chem.* (1990) 265:
28:16898-16912.

OTHER PUBLICATIONS

Elsner, Henrik et al. *Analytical Biochemistry*, (1985) 149/2:575-581.
Sonnenberg, Nahum et al. *Biochemistry (Proc. Nat'l Acad. Sci. USA)* (1977) 74/10:4288-4292.
Turchinsky, M.F. et al. *FEBS Letters* (1974) 38/3:304-307.
Gibson, K. et al. *Nucleic Acids Research* (1987) 15/16:5455-5467.
Meyer, Rich B. et al. *J. Am. Chem. Soc.* (1989) 111/22:8517-8519.
Telser, Joshua et al. *J. Am. Chem. Soc.* (1989) 111/18:7226-7232.
Chemical Abstracts (1980) 92/21:p. 20.
Glass, Robert E. *Gene Function: E. coli and its heritable elements*, Univ. of Calif. Press (1982) pp. 268-312.
Moser, Heinz E. et al. *Research Articles* (1987) Oct. 30:645-650.
Hartley, John A. et al. *biochemistry* (1990) 29/12:2985-2991.
Vlassov, Valentin V. et al. "Sequence-specific chemical modification of double-stranded DNA with alkylating oligodeoxyribonucleotide derivatives" *Gene* (1988) 72:313-322.
Uhlmann, E. et al. *Chemical Reviews* (1990) 90/4:544-584.
Moneesh Chatterjee et al. *J. Am. Chem. Soc.*, (1990) 112:6397-6399.
Shaw, Jeng-Pyng et al. *J. Am. Chem. Soc.*, (1991) 113:7765-7766.
Korre, D.G. et al. *Chemical Reviews* "Oligonucleotide Linked to Reactive Groups", Ed. by J. Cohen. Chapter 8. CRC Press, Inc., (1989) pp. 173-196.
John, Rainier et al. *Chem. Ber.* (1990) 123:133-136.
Orson, Frank M. *Nucleic Acids Research*. (1991) 19/12:3435-3441.
Gamper et al. *Nucl. Acids Res.* 14: 9943, 1986.
Robins et al., *J. Can. J. Chem.*, 60:554 (1982).
Robins et al., *J. Org. Chem.*, 48:1854 (1983).
Dale et al., *Proc. Natl. Acad. Sci. USA*, 70:2238 (1973).
Dale et al., *Biochemistry*, 14:2447 (1975).
Ruth et al., *J. Org. Chem.*, 43:2870 (1978).
Bergstrom et al., *J. Am. Chem. Soc.*, 100:8106 (1978).
Bigge et al., *J. Am. Chem. Soc.*, 102:2033 (1980).
Kobayashi, *Chem. Pharm. Bull.*, 21:941 (1973).
B.R. Baker, "Design of Active-Site-Directed Irreversible Enzyme Inhibitors," John Wiley and Sons Inc., New York. (1967).
Summerton and Bartlett, *J. Mol. Biol.*, 122:145 (1978).
Webb and Matteucci, *Nucleic Acids Res.*, 14:7661 (1986).

Register, James C. III et al. *J. of Bio. Chem.* (1987) 262/26:12812-12820.

Thoung, Nguyen Thanh et al. *Biochimie.* (1985) 67:673-684.

Chang, Susanne et al. *J. of Bio. Chem.* (1988) 263/20:15110-15117.

Knorre, D. G. et al. "complementarily addressed modification of double-stranded DNA in a triple-stranded complex" *Dokl. Akad. Nauk SSSR* (1988) 300/4:1006-9.

Petrie, Charles T. et al. *Bioconjugate Chemistry.* (1991) 2/6:441-446.

Sidwell, Robert W. et al. *Applied Microbiology.* (1968) 16/2:370-392.

Seela, Frank et al. *Nucleic Acids Research.* (1982) 10/4:1389-1397.


(List continued on next page.)

Primary Examiner—Gary L. Kunz
Attorney, Agent, or Firm—Klein & Szekeres, LLP

[57]

ABSTRACT

This invention is directed to novel substituted nucleotide bases with a crosslinking arm which accomplish crosslinking between specific sites on adjoining strands of oligonucleotides or oligodeoxynucleotides. The invention is also directed to oligonucleotides comprising at least one of these crosslinking agents and to the use of the resulting novel oligonucleotides for diagnostic and therapeutic purposes. The crosslinking agents of the invention are of the following formula (I):



wherein,

R_1 is hydrogen, or a sugar moiety or analog thereof optionally substituted at its 3' or its 5' position with a phosphorus derivative attached to the sugar moiety by an oxygen and including groups Q_1 , Q_2 and Q_3 or with a reactive precursor thereof suitable for nucleotide bond formation;

Q_1 is hydroxy, phosphate or diphosphate;

Q_2 is $=O$ or $=S$;

Q_3 is $CH_2—R'$, $S—R'$, $O—R'$, or $N—R'R''$;

each of R' and R'' is independently hydrogen or C_{1-6} alkyl;

B is a nucleic acid base or analog thereof that is a component of an oligonucleotide;

Y is a functional linking group;

each of m and q is independently 0 to 8, inclusive;

r is 0 or 1; and

A' is a leaving group.

This invention is also directed to novel 3,4-disubstituted and 3,4-trisubstituted pyrazolo[3,4-d]pyrimidines and to the use of these nucleic acid bases in the preparation of oligonucleotides. The invention includes nucleosides and mono- and oligonucleotides comprising at least one of these pyrazolopyrimidines, and to the use of the resulting novel oligonucleotides for diagnostic purposes.

Iverson and Dervan. *Proc. Natl. Acad. Sci. USA*, 85:4615 (1988).
Green et al. *Ann Rev. Biochem.*, 55:569 (1986).
Paterson et al., *Proc. Natl. Acad. Sci.*, 74:4370 (1977).
Hastie et al., *Proc. Natl. Acad. Sci.*, 75:1217 (1978).
Zamecnik and Stephenson. *Proc. Natl. Acad. Sci.*, 75:280 (1978).
Stephenson et al., *Proc. Natl. Acad. Sci. USA*, 75:285 (1978).
Zamecnik et al., *Proc. Natl. Acad. Sci. USA*, 83:4143 (1986).
Blake et al., *Biochemistry*, 24:6139 (1985).
Gamper et al., *Natl. Acids Res.*, 14:9943 (1986).
Le Doan et al., *Nucleic Acids Res.*, 15:7749 (1987).
Sonveaux. *Bioorganic Chemistry*, 14:274 (1986).
Jones. in "Oligonucleotide Synthesis, a Practical Approach". M. J. Gait, Ed., IRL Press, pp. 23-34 (1984).
Langer et al., *Proc. Natl. Acad. Sci. USA*, 78:6633 (1981).
Arrand. "Preparation of Nucleic Acid Probes" in *Nucleic Acid Hybridisation, A Practical Approach*, Hames and Higgins, Eds., IRL Press, pp. 17-45 (1985).
Pardue, "In Situ Hybridisation" in *Nucleic Acid Hybridisation, A Practical Approach*, Hames and Higgins, Eds. IRL Press, pp. 179-202 (1985).
Gall and Pardue, *Proc. Natl. Acad. Sci. USA*, 63:378 (1969).
John et al., *Nature*, 223:582 (1969).
"Physical Biochemistry", Freifelder, D., W.H. Freeman & Co., pp. 537-542 (1982).
Tijssen, P., "Practice and Theory of Enzyme Immunoassays. Laboratory Techniques" in *Biochemistry and Molecular Biology*, Burdon, R.H. van Knippenberg, P.H. Eds., Elsevier, pp. 9-20 (1985).
Sinha et al., *Nucleic Acids Res.*, 12:4539 (1984).
Maxam et al., *Proc. Natl. Acad. Sci. USA*, 74:560 (1977).
Busso, Mariano; et al: "Nucleotide Dimers Suppress HIV Expression In Vitro" in: *Aids Research and Human Retroviruses*, vol. 4, No. 6, 1988.
Seela et al. (I), *Helv. Chim. Acta*, 71, 1813-1823 (1988).
Seela et al. (II), *Helv. Chim. Acta*, 71, 1191-1198 (1988).
Seela et al. (III), *Nucleic Acids Research*, 14, 1825-1844 (1986).
Hecht et al. *Biochemistry*, 15, 1005-1015 (1976).
Fieser et al., *Reagents for Organic Synthesis*, John Wiley and Sons, New York, New York, 1967, vol. 1, p. 837.
Kochetkov et al., *Organic Chemistry of Nucleic Acids, Part B*, Plenum Press, New York, New York, 1972, p. 375.
Sinha et al. *Nucleic Acids Research*, 16(6), 2659-2669 (1988).

CROSS-LINKING OLIGONUCLEOTIDES

CROSS REFERENCE TO RELATED APPLICATIONS

5

This application is a continuation of application Ser. No. 08/049,807, filed Apr. 20, 1993, now abandoned which is in turn a continuation of application Ser. No. 07/353,857, filed May 18, 1989, now abandoned, which in turn is a continuation-in-part of application Ser. No. 250,474, filed on 10 Sep. 28, 1988.

BACKGROUND OF THE INVENTION

This invention relates to nucleoside crosslinking agents 15 and to the use of these compounds in the preparation of oligonucleotides. It also relates to derivatives of pyrazolo [3.4-d]pyrimidine which are useful as nucleic acid bases for the preparation of oligonucleotides.

Oligonucleotides are useful as diagnostic probes for the 20 detection of "target" DNA or RNA sequences. In the past, such probes were made up of sequences of nucleic acid containing purine, pyrimidine or 7-deazapurine nucleotide bases (U.S. Pat. No. 4,711,955; Robins et al., *J. Can. J. Chem.*, 60:554 (1982); Robins et al., *J. Org. Chem.* 48:1854 25 (1983)). The method for attaching chemical moieties to these bases has been via an acetoxy-mercuration reaction, which introduces covalently bound mercury atoms into the 5-position of the pyrimidine ring, the C-8 position of the purine ring or the C-7 position of a 7-deazapurine ring (Dale et al., *Proc. Natl. Acad. Sci. USA*, 70:2238 (1973); Dale et al., *Biochemistry*, 14:2447 (1975)), or by the reaction of organomercurial compounds with olefinic compounds in the presence of palladium catalysts (Ruth et al., *J. Org. Chem.*, 43:2870 (1978); Bergstrom et al., *J. Am. Chem. Soc.*, 100:8106 (1978); Bigge et al., *J. Am. Chem. Soc.*, 102:2033 30 (1980)).

The sugar component of oligonucleotide probes has been, until the present, composed of nucleic acid containing ribose or deoxyribose or, in one case, natural β -arabinose (patent 40 publication EP 227,459).

A novel class of nucleotide base, the 3,4-disubstituted and 3,4,6-trisubstituted pyrazolo[3.4-d]-pyrimidines, has now been found which offers several advantages over the prior art. The *de novo* chemical synthesis of the pyrazolopyrimidine and the resulting nucleotide allows for the incorporation of a wide range of functional groups in a variety of different positions on the nucleotide base and for the use of different sugar moieties. Also, adenine, guanine and hypoxanthine analogs are obtained from a single nucleoside precursor. Additionally, the synthesis does not require the use of toxic heavy metals or expensive catalysts. Similar pyrazolo [3.4-d]pyrimidines are known (Kobayashi, *Chem. Pharm. Bull.*, 21:941 (1973)); however, the substituents on the group 45 are different from those of the present invention and their only use is as xanthine oxidase inhibitors. The concept of crosslinkable nucleotide probes for use in therapeutic and diagnostic applications is related to the pioneering work of B. R. Baker, "Design of Active-Site-Directed Irreversible Enzyme Inhibitors," Wiley, N.Y. (1967), who used what 50 was termed "active-site-directed enzyme inhibitors" in chemotherapeutic applications.

In recent years, the concept of incorporating a crosslink in an oligonucleotide has been sporadically discussed in efforts to develop superior sequence probes. Knorre and Vlassov, 65 *Prog. Nucl. Acid Res. Mol. Biol.*, 32:291 (1985), have discussed sequence-directed cross-linking ("complementary

addressed modification") using an N-(2-chloroethyl)-N-methylaniline group attached to either the 3'- or 5'-terminus of oligonucleotides. Sunmerton and Bartlett, *J. Mol. Biol.*, 122:145 (1978) have shown that an 8-atom chain, attached 5 to a cytosine residue at its C-4 position and terminating in the highly reactive bromomethyl ketone group, can crosslink to the N-7 of guanosine.

Webb and Matteucci, *Nucleic Acids Res.*, 14:7661 (1986), have prepared oligonucleotides containing a 5-methyl-N,N-ethanocytosine base which is capable of slow crosslinking with a complementary strand. In a conceptually related alkylation via a linker arm within a DNA hybrid, Iverson and Dervan, *Proc. Natl. Acad. Sci. USA*, 85:4615 (1988), have shown opposite strand methylation, triggered by BrCN 15 activation of a methylthio ether, predominately on a guanine base located two pairs from the base bearing the linker.

Oligonucleotides may be used as chemotherapeutic agents to control the expression of gene sequences unique to an invading organism, such as a virus, a fungus, a parasite 20 or a bacterium. In nature, some RNA expression in bacteria is controlled by "antisense" RNA, which exerts its effect by forming RNA:RNA hybrids with complementary target RNAs and modulating or inactivating their biological activity. A variety of recent studies using plasmid vectors for the 25 introduction of antisense RNAs into eukaryotic cells have shown that they effectively inhibit expression of mRNA targets *in vivo* (reviewed in Green, et al., *Ann. Rev. Biochem.*, 55: 569-597 (1986)). Additionally, a specific mRNA amongst a large number of mRNAs can be selectively 30 inactivated for protein synthesis by hybridization with a complementary DNA restriction fragment, which binds to the mRNA and prevents its translation into protein on ribosomes (Paterson, et al., *Proc. Natl. Acad. Sci.* 74: 4370-4374 (1977); Hastie et al., *Proc. Natl. Acad. Sci.* 75: 35 1217-1221 (1978)).

In the first demonstration of the concept of using sequence-specific, antisense oligonucleotides as regulators of gene expression and as chemotherapeutic agents, Zamecnik and Stephenson, *Proc. Natl. Acad. Sci. USA*, 75:280 (1978), showed that a small antisense oligodeoxynucleotide 40 probe can inhibit replication of Rous Sarcoma virus in cell culture, and that RSV viral RNA translation is inhibited under these conditions (Stephenson et al., *Proc. Natl. Acad. Sci. USA* 75:285 (1978)). Zamecnik et al., *Proc. Natl. Acad. Sci. USA*, 83:4143 (1986), have also shown that oligonucleotides complementary to portions of the HIV genome are 45 capable of inhibiting protein expression and virus replication in cell culture. Inhibition of up to 95% was obtained with oligonucleotide concentrations of about 70 μ M. Importantly, 50 they showed with labeled phosphate studies that the oligonucleotides enter cells intact and are reasonably stable to metabolism.

Uncharged methylphosphonate oligodeoxynucleotides 55 with a sequence complementary to the initiation codon regions of rabbit globin mRNA inhibited the translation of the mRNA in both cell-free systems and in rabbit reticulocytes (Blake et al., *Biochemistry* 24:6139 (1985)). Another uncharged methylphosphonate oligonucleotide analog, an 60 8-nucleotide sequence complementary to the acceptor splice junction of a mRNA of Herpes simplex virus, Type 1, can inhibit virus replication in intact Vero cells. However, fairly high concentrations (>25 mM) of this nonionic probe were required for this inhibition.

65 Although the impact of crosslinking oligonucleotides in the chemotherapeutic field might be of great significance, their impact in DNA probe-based diagnostics is of equally

great importance. The ability to covalently crosslink probe-target hybrids has the potential to dramatically improve background and sensitivity limits in diagnostic assays as well as permit novel assay formats. Specific innovations (discussed previously by Gamper et al., *Nucl. Acids Res.*, 14, 5 9943 (1988)) include:

- (a) incorporation of a denaturing wash step to remove background;
- (b) use of the crosslink as an additional tier of discrimination; 10
- (c) crosslinking occurring at or near the melting temperature of the expected hybrid to insure exquisite specificity and to substantially reduce secondary structure in the target, thereby increasing the efficiency of hybrid formation; and 15
- (d) novel solution hybridization formats as exemplified by the Reverse Southern protocol.

The concept of crosslinking, however, suggests potential problems that must be circumvented. For instance, the oligonucleotide containing a crosslinking arm might 20 covalently bond to the target sequence so readily that mismatching of sequences will occur, possibly resulting in host toxicity. On the other hand, the crosslinking reaction must be fast enough to occur before correctly matched sequences can dissociate. 25

This issue can be addressed by constructing an oligonucleotide that, upon hybridization, results in a duplex whose T_m is just above the physiological temperature of 37° C. Thus, even a single mismatched base will prevent hybrid 30 formation and therefore crosslinkage. The optimization can be accomplished by judicious choice of oligonucleotide length and base composition, as well as position of the modified base within the probe. The probe must be long enough, however, to insure specific targeting of a unique site. 35

European Patent Application No. 86309090.8 describes the formation of chemically modified DNA probes such as 5-substituted uridyl in which the substituent does not crosslink but contains a chemical or physical reporter group. 40 WO8707611 describes a process for labeling DNA fragments such as by chemically modifying the fragment followed by reaction with a fluorescent dye. Yabusaki et al. in U.S. Pat. No. 4,599,303 disclose a scheme for covalently crosslinking oligonucleotides such as by formation of furocoumarin monoadducts of thymidine which are made to 45 covalently bond to other nucleotides upon photoexcitation. EP 0259186 describes adducts of macromolecules and biotin which can be used as crosslinking nucleic acid hybridization probes. WO8503075 describes crosslinking disulfonic esters 50 useful as nucleic acid fragmentation agents. DE3310337 describes the covalent crosslinking of single-stranded polynucleotides to such macromolecules as proteins with the resulting complex subsequently used as a marker in hybridization experiments in the search for complementary 55 sequences in foreign polynucleotides.

A need exists for probe oligonucleotides, consisting of sufficient base sequences to identify target sequences with high specificity, that are provided with one or more crosslinking arms which readily form covalent bonds with specific complementary bases. Such oligonucleotides may 60 be used as highly selective probes in hybridization assays. The oligonucleotides may also be used as antisensing agents of RNAs, e.g., in chemotherapy.

SUMMARY OF THE INVENTION

This invention is directed to crosslinking agents which accomplish crosslinking between specific sites on adjoining

strands of oligonucleotides. The crosslinking reaction observed is of excellent specificity. The invention is also directed to oligonucleotides comprising at least one of these crosslinking agents and to the use of the resulting novel 5 oligonucleotides for diagnostic and therapeutic purposes.

More particularly, the crosslinking agents of this invention are derivatives of nucleotide bases with a crosslinking arm and are of the following formula (I):

10



wherein,

15 R_1 is hydrogen, or a sugar moiety or analog thereof optionally substituted at its 3' or its 5' position with a phosphorus derivative attached to the sugar moiety by an oxygen and including groups Q_1 , Q_2 and Q_3 , or with a reactive precursor thereof suitable for nucleotide bond formation;

20 Q_1 is hydroxy, phosphate or diphosphate;
 Q_2 is $=O$ or $=S$;
 Q_3 is $CH_2—R'$, $S—R'$, $O—R'$, or $N—R'R''$;
each of R' and R'' is independently hydrogen or c_{1-6} alkyl;
25 B is a nucleic acid base or analog thereof that is a component of an oligonucleotide;
 Y is a functional linking group;
each of m and q is independently 0 to 8, inclusive;
 r is 0 or 1; and
30 A' is a leaving group.

The invention also provides novel oligonucleotides comprising at least one of the above nucleotide base derivatives of formula I.

35 Nucleotides of this invention and oligonucleotides into which the nucleotides have been incorporated may be used as probes. Since probe hybridization is reversible, albeit slow, it is desirable to ensure that each time a probe hybridizes with the correct target sequence, the probe is irreversibly attached to that sequence. The covalent 40 crosslinking arm of the nucleotide bases of the present invention will permanently modify the target strand, or cause depurination. As such, the oligonucleotides of this invention are useful in the identification, isolation, localization 45 and/or detection of complementary nucleic acid sequences of interest in cell-free and cellular systems. Therefore, the invention further provides a method for identifying target nucleic acid sequences, which method comprises utilizing an oligonucleotide probe comprising at least one of a labeled nucleotide base of the present invention.

50 This invention also provides novel substituted pyrazolo [3,4-d]pyrimidines which are useful as a nucleotide base in preparing nucleosides and nucleotides, rather than the natural purine or pyrimidine bases or the deazapurine analogs.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts a modified deoxyuridine residue of an oligodeoxynucleotide crosslinked via an acetamidopropyl sidearm to a deoxyguanosine residue located two sites away from the complementary base along the 5' direction.


FIG. 2 depicts an autoradiogram of ^{32}P labeled HPV target and crosslinked product following cleavage at the 3' side of the crosslinked guanosine. Lane 1: 32P-labeled 55 15-mer size marker. Lane 2: 24 hour reaction at 20° C. Lane 3: 72 hour reaction at 20° C. Lane 4: 24 hour reaction at 30° C. Lane 5: 72 hour reaction at 30° C. Reactions were

quenched with 2-aminoethanethiol and treated with piperidine sol on to effect cleavage.

FIG. 3 depicts an autoradiogram of ^{32}P labeled HPV target and crosslinked product showing hybrid separation by denaturing polyacrylamide gel electrophoresis. Lane 1: Control ^{32}P -labeled CMV target. Lane 2: 24 hour reaction at 20 ° C. Lane 3: 72 hour reaction at 20 ° C. Lane 4: 24 hour reaction at 30 ° C. Lane 5: 72 hour reaction at 30 ° C. Reaction solutions were treated with 2-aminoethanethiol, which quenches the iodoacetamido group.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides novel substituted nucleotide bases with a crosslinking arm which are useful in preparing nucleosides and nucleotides and are useful as crosslinking agents. The substituted bases are of the following formula (I):



wherein:

R_1 is hydrogen, or a sugar moiety or analog thereof optionally substituted at its 3' or its 5' position with a phosphorus derivative attached to the sugar moiety by an oxygen and including groups Q_1 , Q_2 and Q_3 , or with a reactive precursor thereof suitable for nucleotide bond formation;

Q_1 is hydroxy, phosphate or diphosphate;

Q_2 is $=\text{O}$ or $=\text{S}$;

Q_3 is $\text{CH}_2-\text{R}'$, $\text{S}-\text{R}'$, $\text{O}-\text{R}'$, or $\text{N}-\text{R}'\text{R}''$; each of R' and R'' is independently hydrogen or C_{1-6} alkyl;

B is a nucleic acid base or analog thereof that is a component of an oligonucleotide;

Y is a functional linking group;

each of m and q is independently 0 to 8, inclusive;

r is 0 or 1; and

A' is a leaving group.

In the practice of the present invention, the sugar moiety or analog thereof is selected from those useful as a component of a nucleotide. Such a moiety may be selected from, for example, ribose, deoxyribose, pentose, deoxypentose, hexose, deoxyhexose, glucose, arabinose, pentofuranose, xylose, lyxose, and cyclopentyl. The sugar moiety is preferably ribose, deoxyribose, arabinose or 2'-O-methylribose and embraces either anomer, α or β .

The phosphorus derivative attached to the sugar moiety is conveniently selected from, for example, monophosphate, diphosphate, triphosphate, alkyl phosphate, alkane phosphonate, phosphorothioate, phosphorodithioate, and the like.

A reactive precursor suitable for internucleotide bond formation is one which is useful during chain extension in the synthesis of an oligonucleotide. Reactive groups particularly useful in the present invention are those containing phosphorus. Phosphorus-containing groups suitable for internucleotide bond formation are preferably alkyl phosphochloridites, alkyl phosphites or alkylphosphoramidites. Alternatively, activated phosphate diesters may be employed for this purpose.

The nucleic acid base or analog thereof (B) may be chosen from the purines, the pyrimidines, the deazapurines and the pyrazolopyrimidines. It is preferably selected from uracil-5-yl, cytosin-5-yl, adenin-7-yl, adenin-8-yl, guanin-7-yl, guanin-8-yl, 4-aminopyrrolo[2.3-d]pyrimidin-5-yl, 2-amino-4-oxopyrrolo[2.3-d]pyrimidin-5-yl, 4-aminopyrazolo[3.4-d]pyrimidin-3-yl or 4-amino-6-oxopyrazolo[3.4-d]pyrimidin-3-yl, where the purines are attached to the sugar moiety of the oligonucleotides via the 9-position, the pyrimidines via the 1-position, the pyrrolopyrimidines via the 7-position and the pyrazolopyrimidines via the 1-position.

The functional linking group Y may be chosen from nucleophilic groups such as oxy, thio, amino or chemically blocked derivatives thereof, for example trifluoroacetamido, phthalimido, CONR', NR'CO, and SO₂NR', where R'=H or C₁₋₆alkyl. Such functionalities, including aliphatic or aromatic amines, exhibit nucleophilic properties and are capable of serving as a point of attachment of the —(CH₂)_m—A' group. Amino groups and blocked derivatives thereof are preferred.

The leaving group A' may be chosen from, for example, such groups as chloro, bromo, iodo, SO₂R'', or S'R''R'', where each of R'' and R''' is independently C₁₋₆alkyl or aryl or R'' and R''' together form a C₁₋₆alkylene bridge. Chloro, bromo and iodo are preferred. The leaving group will be altered by its leaving ability. Depending on the nature and reactivity of the particular leaving group, the group to be used is chosen in each case to give the desired specificity of the irreversibly binding probes.

Examination of double-stranded DNA by ball-and-stick models and high resolution computer graphics indicates that the 7-position of the purines and the 5-position of the pyrimidines lie in the major groove of the B-form duplex of double-stranded nucleic acids. These positions can be substituted with side chains of considerable bulk without interfering with the hybridization properties of the bases. These side arms may be introduced either by derivatization of dThd or dcyd, or by straightforward total synthesis of the heterocyclic base, followed by glycosylation. These modified nucleosides may be converted into the appropriate activated nucleotides for incorporation into oligonucleotides with an automated DNA synthesizer. With the pyrazolo[3,4-d]pyrimidines, which are analogs of adenine, the crosslinking arm is attached at the 3-position, which is equivalent to the 7-position of purine.


The crosslinking side chain should be of sufficient length to reach across the major groove from a purine 7- or 8-position, pyrimidine 5-position, pyrrolopyrimidine 5-position or pyrazolopyrimidine 3-position and reacting with the N-7 of a purine (preferably guanine) located above (on the oligomer 3'-side) the base pair containing the modified analog. Thus, the side chain should be of at least three atoms, preferably of at least five atoms and more preferably of at least six atoms in length. A generally preferred length of the side chain is from about 5 to about 9 carbon atoms.

To optimize strand crosslinking, it would be desirable to have the target strand base which is being attacked paired to the first or second base which is on the 3' side of the modified base in the oligonucleotide containing the crosslinking arm. For example, in the case where the target strand base under

attack is a guanine, the target sequence for a probe containing a modified uracil should contain the complement GZA (preferably GGA), where Z is any base, with the probe oligonucleotide containing UZC (preferably UCC), where U is dUrd 5'-substituted with the crosslinking arm. In oligonucleotides containing crosslinking adenine derivatives, for example, the adenine-modified AZ¹C triplet would target GZ¹T, where Z¹ is any base.


It has been found that when the modified base containing the crosslinking arm is a uracil and the target sequence is GGA, alkylation of the second guanine on the target's 5' side of the crosslinker-modified base pair is the exclusive action observed (as shown in FIG. 1). The crosslinking reaction seems to be very specific for the "best fit" of electrophile to nucleophile, i.e., two or more guanine residues may need to neighbor the complement of the modified base to discover the site of alkylation.

Two classes of modified 2'-deoxyribonucleosides have demonstrated particular usefulness in the present invention for incorporation into oligonucleotides as sequence-directed crosslinking agents. The first class is the 5-substituted-2'-deoxyuridines whose general structure is presented below:




The 5-(substituted)-2'-deoxyuridines may be prepared by the routes shown in Schemes 1 and 2.

Scheme 1




-continued
Scheme 1



For example, the general procedure of Robins et al. (*J. Can. J. Chem.*, 60:554 (1982); *J. Org. Chem.*, 48:1854 (1983)) may be adapted, as shown in Scheme 1, to the palladium-mediated coupling of a substituted 1-alkyne (XXI) to 5-iodo-2'-deoxyuridine (XX) to give the acetylenic product (XXII). The acetylenic dUrd analog XXII is reduced, with Raney nickel for example, to give the saturated compound (XXIII), which is then used for direct conversion to a reagent for use on an automated DNA synthesizer, as described below.


Scheme 2




60 When 5-chloromercurio-2'-deoxyuridine (XXIV) is used as a starting compound, it cannot be directly coupled to an olefin group to give the olefinic compound (XXVII) by palladium-catalyzed coupling with functionalized olefins. Instead, as shown in Scheme 2, a substituted alkene (XXV) and 5-chloromercurio-2'-deoxyuridine (XXIV) are reacted together with methanol to give the alpha-methoxy adduct (XXVI), which is converted to the olefinic compound

XXVII by trifluoroacetic acid and trifluoroacetic anhydride. Reduction gives the saturated compound (XXIII), to be converted to the DNA synthesizer-ready reagent as described below.

The second class of modified nucleoside is a group of 5 2'-deoxy-4-aminopyrazolo[3,4-d]pyrimidine derivatives. The general structure of these derivatives is presented below:



The above compounds are derived from a novel group of derivatives of 3,4-disubstituted and 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidines. The 3,4-di-substituted and 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidines and their synthesis are disclosed in commonly owned, copending application Ser. No. 250,474, the entire disclosure of which is incorporated herein by reference. They have the following formula (I):



wherein,

R₁ is hydrogen, or a sugar moiety or analog with a phosphorus derivative attached to the sugar moiety by an oxygen and including groups Q₁, Q₂ and Q₃, or with a reactive precursor thereof suitable for nucleotide bond formation; provided that when R₃ is hydrogen, then R cannot be hydrogen;

Q₁ is hydroxy, phosphate or diphosphate;

Q₂ is =O or =S;

Q₃ is CH₂-R', S-R', O-R', or N-R'R";

each of R' and R" is independently hydrogen or C₁₋₆alkyl;

R₃ is hydrogen or the group -W-(X)_n-A;

each of W and X is independently a chemical linker arm;

A is an intercalator, a metal ion chelator, an electrophilic crosslinker, a photoactivatable crosslinker, or a reporter group;

each of R₄ and R₆ is independently H, OR, SR, NHOR, NH₂, or NH(CH₂)_nNH₂;

R is H or C₁₋₆alkyl;

n is zero or one; and

t is zero to twelve.

The synthesis of 3,4-disubstituted and 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidine nucleosides and their use as reagents for incorporation into nucleic acids either enzymatically or via chemical synthesis offers several advantages over current procedures. The de novo chemical synthesis of the nucleotide allows for the incorporation of a wide range of functional groups (e.g., NH₂, SH, OH, halogen, COOH,

CN, CONH₂) and the use of different sugar moieties. Also, adenine, guanine, and hypoxanthine analogs are obtained from a single nucleoside precursor. And, the synthesis does not require the use of toxic heavy metals or expensive 5 catalysts.

In the practice of the present invention, the sugar moiety or its analog is selected from those useful as a component of a nucleotide. Such a moiety may be selected from, for example, pentose, deoxypentose, hexose, deoxyhexose, 10 ribose, deoxyribose, glucose, arabinose, pentofuranose, xylose, lyxose, and cyclopentyl. The sugar moiety is preferably ribose, deoxyribose, arabinose or 2'-O-methylribose and embraces either anomer, α or β .

The phosphorus derivative attached to the sugar moiety is conveniently selected from, for example, monophosphate, 15 diphosphate, triphosphate, alkyl phosphate, alkanephosphonate, phosphorothioate, phosphorodithioate, and the like.

A reactive precursor suitable for internucleotide bond formation is one which is useful during chain extension in 20 the synthesis of an oligonucleotide. Reactive groups particularly useful in the present invention are those containing phosphorus. Phosphorus-containing groups suitable for internucleotide bond formation are preferably alkyl phosphochloridites, alkyl phosphites or alkylphosphoramidites. Alternatively, activated phosphate diesters may be 25 employed for this purpose.

In the above formula I, a chemical linker arm (W alone or together with X) serves to make the functional group (A) more able to readily interact with antibodies, detector 30 proteins, or chemical reagents, for example. The linkage holds the functional group away from the base when the base is paired with another within the double-stranded complex. Linker arms may include alkylene groups of 1 to 12 carbon atoms, alkenylene groups of 2 to 12 carbon atoms and 1 or 35 2 olefinic bonds, alkynylene groups of 2 to 12 carbon atoms and 1 or 2 acetylenic bonds, or such groups substituted at a terminal point with nucleophilic groups such as oxy, thio, amino or chemically blocked derivatives thereof (e.g., trifluoroacetamido, phthalimido, CONR', NR'CO, and 40 SO₂NR', where R'=H or C₁₋₆alkyl). Such functionalities, including aliphatic or aromatic amines, exhibit nucleophilic properties and are capable of serving as a point of attachment of the functional group (A).

The linker arm moiety (W alone or together with X) is 45 preferably of at least three atoms and more preferably of at least five atoms. The terminal nucleophilic group is preferably amino or chemically blocked derivatives thereof.


Intercalators are planar aromatic bi-, tri- or polycyclic molecules which can insert themselves between two adjacent base pairs in a double-stranded helix of nucleic acid. 50 Intercalators have been used to cause frameshift mutations in DNA and RNA. It has also recently been shown that when an intercalator is covalently bound via a linker arm ("tethered") to the end of a deoxyoligonucleotide, it 55 increases the binding affinity of the oligonucleotide for its target sequence, resulting in strongly enhanced stability of the complementary sequence complex. At least some of the tethered intercalators also protect the oligonucleotide against exonucleases, but not against endonucleases. See, 60 Sun et al., *Nucleic Acids Res.*, 15:6149-6158 (1987); Le Doan et al., *Nucleic Acids Res.*, 15:7749-7760 (1987). Examples of tetherable intercalating agents are oxazolopyridocarbazole, acridine orange, proflavine, acriflavine and derivatives of proflavine and acridine such as 65 3-azido-6-(3-bromopropylamino)acridine, 3-amino-6-(3-bromopentylamino)acridine, and 3-methoxy-6-chloro-9-(5-hydroxypentylamino)acridine.

Oligonucleotides capable of crosslinking to the complementary sequence of target nucleic acids are valuable in chemotherapy because they increase the efficiency of inhibition of mRNA translation or gene expression control by covalent attachment of the oligonucleotide to the target sequence. This can be accomplished by crosslinking agents being covalently attached to the oligonucleotide, which can then be chemically activated to form crosslinkages which can then induce chain breaks in the target complementary sequence, thus inducing irreversible damage in the sequence. Examples of electrophilic crosslinking moieties include alpha-halocarbonyl compounds, 5 2-chloroethylamines and epoxides.

When oligonucleotides comprising at least one nucleotide base moiety of the invention are utilized as a probe in nucleic acid assays, a label is attached to detect the presence of hybrid polynucleotides. Such labels act as reporter groups and act as means for detecting duplex formation between the target nucleotides and their complementary oligonucleotide probes. 15 20


A reporter group as used herein is a group which has a physical or chemical characteristic which can be measured or detected. Detectability may be provided by such characteristics as color change, luminescence, fluorescence, or radioactivity; or it may be provided by the ability of the reporter group to serve as a ligand recognition site. 25

The pyrazolopyrimidines of the present invention of formula I where R₁ is hydrogen may be prepared by the procedures outlined below and as set forth by Kobayashi in *Chem. Pharm. Bull.*, 21:941-951 (1973), the disclosure of 30 which is incorporated herein by reference.




In general, malononitrile (III) is treated with acyl halide (II) in the presence of a base to yield acylmalononitrile (IV), 55 which is subsequently methylated with dimethyl sulfate or diazomethane, for example, to give the substituted methoxymethylenemalononitrile (V). This compound is then reacted with hydrazine hydrate in boiling alcohol to give the 3-substituted-5-aminopyrazole-4-carbonitrile (VI), which is 60 treated with cold concentrated sulfuric acid to give the 3-substituted-5-aminopyrazole-4-carboxamide (VII).

The carboxamide (VII) may alternatively be prepared by treating cyanoacetamide (XII) with acid halide (II) to give the acylcyanoacetamide (XIII), which is then methylated, 65 and the resulting methoxy compound (XIV) is reacted with hydrazine hydrate.



Syntheses of pyrazolo[3.4-d]pyrimidines are accomplished from the two pyrazole intermediates, VI and VII. Thus, 3,4-disubstituted pyrazolo[3.4-d]pyrimidines (VIII and X) are obtained by treating the corresponding VI and VII with boiling formamide. Alternatively, VI may be treated with dialkoxymethyl ester of a carboxylic acid, at room temperature or above room temperature, and then with ammonia to give VIII and VII may be treated with dialkoxymethyl ester of a carboxylic acid (without subsequent ammonia treatment), at room temperature or above room temperature, to give compound X. 3,4,6-Trisubstituted pyrazolo[3.4-d]pyrimidines (IX and XI) are obtained by fusing the corresponding VI and VII with urea and thiourea ($\text{H}_2\text{N}_2\text{C}=\text{R}_6$ (where R_6 is O or S). Alternatively, VI and VII may be treated with an alkyl xanthate salt such as potassium ethyl xanthate and with alkyl halide such as methyl iodide, at a temperature above room temperature, followed by oxidation by a peroxide such as m -chloroperbenzoic acid (MCPBA) and subsequent treatment with ammonia to give IX and XI respectively, where R_6 is NH_2 .



The compounds of formula I may be recovered from the reaction mixture in which they are formed by established procedures.

In the compounds of formula I where R_1 is a sugar moiety, the sugar may be either added to the 1-position of the

pyrazole VI or VII prior to further treatment or added to the 1-position of the pyrazolo[3.4-d]pyrimidine VIII, IX, X or XI. To add the sugar, the pyrazole or pyrazolopyrimidine is treated with sodium hydride and then with the glycosyl 5
halide of the blocked sugar.

Oligonucleotides of the present invention may comprise at least one and up to all of their nucleotides from the substituted pyrazolo[3.4-d]pyrimidines of formula I and/or at least one and up to all of their nucleotides from the substituted nucleotide bases of formula Γ . 10

To prepare oligonucleotides, protective groups are introduced onto the nucleosides of formula I or formula Γ and the nucleosides are activated for use in the synthesis of oligonucleotides. The conversion to protected, activated forms follows the procedures as described for 2'-deoxynucleosides 15 in detail in several reviews. See, Sonveaux, *Bioorganic Chemistry*, 14: 274-325 (1986); Jones, in "Oligonucleotide Synthesis, a Practical Approach", M. J. Gait, Ed., IRL Press, p. 23-34 (1984).

The activated nucleotides are incorporated into oligonucleotides in a manner analogous to that for DNA and RNA nucleotides, in that the correct nucleotides will be sequentially linked to form a chain of nucleotides which is complementary to a sequence of nucleotides in target DNA or RNA. The nucleotides may be incorporated either enzymatically or 20 via chemical synthesis. The nucleotides may be converted to their 5'-O-dimethoxytrityl-3'-(N,N-diisopropyl) phosphoramidite cyanoethyl ester derivatives, and incorporated into synthetic oligonucleotides following the procedures in "Oligonucleotide Synthesis: A Practical Approach", 25 supra. The N-protecting groups are then removed, along with the other oligonucleotide blocking groups, by post-synthesis aminolysis, by procedures generally known in the art.

In a preferred embodiment, the activated nucleotides may 30 be used directly on an automated DNA synthesizer according to the procedures and instructions of the particular synthesizer employed. The oligonucleotides may be prepared on the synthesizer using the standard commercial phosphoramidite or H-phosphonate chemistries. 35

In another preferred embodiment, the amino-pyrazolopyrimidine nucleotide triphosphates may substitute for an adenine using the nick translation procedure, as described by Langer et al., *Proc. Natl. Acad. Sci. USA*, 78:6633-6637 (1981), the disclosure of which is incorporated herein by reference. 40

The leaving group, such as a haloacyl group, may be added to the aminoalkyl tails ($-\text{CH}_2\text{q}-\text{Y}$) following incorporation into oligonucleotides and removal of any blocking groups. For example, addition of an 45 α -haloacetamide may be verified by a changed mobility of the modified compound on HPLC, corresponding to the removal of the positive charge of the amino group, and by subsequent readdition of a positive charge by reaction with 2-amino-ethanethiol to give a derivative with reverse phase 50 HPLC mobility similar to the original aminoalkyl-oligonucleotide.

In specific embodiments, each of the following electrophilic leaving groups were attached to an aminopropyl group on human papillomavirus (HPV) probes: bromoacetyl, 55 iodoacetyl and the less reactive but conformationally more flexible 4-bromobutyryl. Bromoacetyl and iodoacetyl were found to be of equal reactivity in crosslinking.

An oligonucleotide probe according to the invention includes at least one labeled substituted pyrazolo[3.4-60 d]pyrimidine nucleotide moiety of formula I and/or at least one labeled substituted nucleotide base of formula Γ . 65

Probes may be labeled by any one of several methods typically used in the art. A common method of detection is the use of autoradiography with ³H, ¹²⁵I, ³⁵S, ¹⁴C, or ³²P labeled probes or the like. Other reporter groups include 5 ligands which bind to antibodies labeled with fluorophores, chemiluminescent agents, and enzymes. Alternatively, probes can be conjugated directly with labels such as fluorophores, chemiluminescent agents, enzymes and enzyme substrates. Alternatively, the same components may 10 be indirectly bonded through a ligand-antiligand complex, such as antibodies reactive with a ligand conjugated with label. The choice of label depends on sensitivity required, ease of conjugation with the probe, stability requirements, and available instrumentation.

15 The choice of label dictates the manner in which the label is incorporated into the probe. Radioactive probes are typically made using commercially available nucleotides containing the desired radioactive isotope. The radioactive nucleotides can be incorporated into probes, for example, by 20 using DNA synthesizers, by nick-translation, by tailing of radioactive bases to the 3' end of probes with terminal transferase, by copying M13 plasmids having specific inserts with the Klenow fragment of DNA polymerase in the presence of radioactive dNTP's, or by transcribing RNA 25 from templates using RNA polymerase in the presence of radioactive rNTP's.

Non-radioactive probes can be labeled directly with a signal (e.g., fluorophore, chemiluminescent agent or enzyme) or labeled indirectly by conjugation with a ligand. 30 For example, a ligand molecule is covalently bound to the probe. This ligand then binds to a receptor molecule which is either inherently detectable or covalently bound to a detectable signal, such as an enzyme or photoreactive compound. Ligands and antiligands may be varied widely. 35 Where a ligand has a natural "antiligand", namely ligands such as biotin, thyroxine, and cortisol, it can be used in conjunction with its labeled, naturally occurring antiligand. Alternatively, any haptenic or antigenic compound can be used in combination with a suitably labeled antibody. A 40 preferred labeling method utilizes biotin-labeled analogs of oligonucleotides, as disclosed in Langer et al., *Proc. Natl. Acad. Sci. USA*, 78:6633-6637 (1981), which is incorporated herein by reference.

Enzymes of interest as reporter groups will primarily be 45 hydrolases, particularly phosphatases, esterases, ureases and glycosidases, or oxidoreductases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, rare earths, etc. Chemiluminescers include 50 luciferin, acridinium esters and 2,3-dihydrophthalazinediones, e.g., luminol.

The specific hybridization conditions are not critical and will vary in accordance with the investigator's preferences and needs. Various hybridization solutions may be 55 employed, comprising from about 20% to about 60% volume, preferably about 30%, of a polar organic solvent. A common hybridization solution employs about 30-60% v/v formamide, about 0.5 to 1M sodium chloride, about 0.05 to 0.1M buffers, such as sodium citrate, Tris HCl, PIPES or 60 HEPES, about 0.05% to 0.5% detergent, such as sodium dodecylsulfate, and between 1-10 mM EDTA, 0.01% to 5% ficoll (about 300-500 kdal), 0.1% to 5% polyvinylpyrrolidone (about 250-500 kdal), and 0.01% to 10% bovine serum albumin. Also included in the typical hybridization solution 65 will be unlabeled carrier nucleic acids from about 0.1 to 5 mg/ml, e.g., partially fragmented calf thymus or salmon sperm DNA, and/or partially fragmented yeast RNA and

optionally from about 0.5% to 2% wt./vol. glycine. Other additives may also be included, such as volume exclusion agents which include a variety of polar water-soluble or swellable agents, such as anionic polyacrylate or polymethylacrylate, and charged saccharidic polymers, such as dextran sulfate.

The particular hybridization technique is not essential to the invention. Hybridization techniques are generally described in "Nucleic Acid Hybridization. A Practical Approach", Hames and Higgins, Eds., IRL Press, 1985; Gall and Pardue, *Proc. Natl. Acad. Sci. U.S.A.*, 63:378-383 (1969); and John et al., *Nature*, 223:582-587 (1969). As improvements are made in hybridization techniques, they can readily be applied.

The amount of labeled probe which is present in the hybridization solution may vary widely. Generally, substantial excesses of probe over the stoichiometric amount of the target nucleic acid will be employed to enhance the rate of binding of the probe to the target DNA.

Various degrees of stringency of hybridization can be employed. As the conditions for hybridization become more stringent, there must be a greater degree of complementarity between the probe and the target for the formation of a stable duplex. The degree of stringency can be controlled by temperature, ionic strength, the inclusion of polar organic solvents, and the like. For example, temperatures employed will normally be in the range of about 20° to 80° C., usually 25° to 75° C. For probes of 15-50 nucleotides in 50% formamide, the optimal temperature range can vary from 22°-65° C. With routine experimentation, one can define conditions which permit satisfactory hybridization at room temperature. The stringency of hybridization is also conveniently varied by changing the ionic strength and polarity of the reactant solution through manipulation of the concentration of formamide within the range of about 20% to about 50%.

Treatment with ultrasound by immersion of the reaction vessel into commercially available sonication baths can oftentimes accelerate the hybridization rates.

After hybridization at a temperature and time period appropriate for the particular hybridization solution used, the glass, plastic, or filter support to which the probe-target hybrid is attached is introduced into a wash solution typically containing similar reagents (e.g., sodium chloride, buffers, organic solvents and detergent), as provided in the hybridization solution. These reagents may be at similar concentrations as the hybridization medium, but often they are at lower concentrations when more stringent washing conditions are desired. The time period for which the support is maintained in the wash solutions may vary from 50 minutes to several hours or more.

Either the hybridization or the wash medium can be stringent. After appropriate stringent washing, the correct hybridization complex may now be detected in accordance with the nature of the label.

The probe may be conjugated directly with the label. For example, where the label is radioactive, the support surface with associated hybridization complex substrate is exposed to X-ray film. Where the label is fluorescent, the sample is detected by first irradiating it with light of a particular wavelength. The sample absorbs this light and then emits light of a different wavelength which is picked up by a detector ("Physical Biochemistry", Freifelder, D., W. H. Freeman & Co., 1982, pp. 537-542). Where the label is an enzyme, the sample is detected by incubation with an appropriate substrate for the enzyme. The signal generated may be a colored precipitate, a colored or fluorescent soluble

material, or photons generated by bioluminescence or chemiluminescence. The preferred label for dipstick assays generates a colored precipitate to indicate a positive reading. For example, alkaline phosphatase will dephosphorylate 5 indoxyl phosphate which then will participate in a reduction reaction to convert tetrazolium salts to highly colored and insoluble formazans.

10 Detection of a hybridization complex may require the binding of a signal generating complex to a duplex of target and probe polynucleotides or nucleic acids. Typically, such binding occurs through ligand and antiligand interactions as between a ligand-conjugated probe and an antiligand conjugated with a signal. The binding of the signal generation complex is also readily amenable to accelerations by exposure to ultrasonic energy.

15 The label may also allow indirect detection of the hybridization complex. For example, where the label is a hapten or antigen, the sample can be detected by using antibodies. In these systems, a signal is generated by attaching fluorescent or enzyme molecules to the antibodies or in some cases, by 20 attachment to a radioactive label (Tijssen, P., "Practice and Theory of Enzyme Immunoassays. Laboratory Techniques in Biochemistry and Molecular Biology", Burdon, R. H., van Knippenberg, P. H., Eds., Elsevier, 1985, pp. 9-20).

25 The amount of labeled probe present in the hybridization solution may vary widely, depending upon the nature of the label, the amount of the labeled probe that can reasonably bind to the cellular target nucleic acid, and the precise stringency of the hybridization medium and/or wash medium. Generally, substantial probe excesses over the 30 stoichiometric amount of the target will be employed to enhance the rate of binding of the probe to the target nucleic acids.

35 The invention is also directed to a method for identifying target nucleic acid sequences, which method comprises utilizing an oligonucleotide probe including at least one labeled substituted nucleotide moiety of formula I and/or formula Γ .

In one embodiment, the method comprises the steps of:

- 40 (a) denaturing nucleic acids in the sample to be tested;
- (b) hybridizing to the target nucleic acids an oligonucleotide probe including at least one labeled substituted nucleotide moiety of formula I or formula Γ , wherein the probe comprises a sequence complementary to that of the target nucleic acids;
- 45 (c) washing the sample to remove unbound probe;
- (d) incubating the sample with detection agents; and
- (e) inspecting the sample.

The above method may be conducted following procedures well known in the art.

50 An assay for identifying target nucleic acid sequences utilizing an oligonucleotide probe including at least one labeled substituted nucleotide moiety of formula I and/or formula Γ and comprising the above method is contemplated for carrying out the invention. Such an assay may be 55 provided in kit form. For example, a typical kit will include a probe reagent component comprising an oligonucleotide including at least one labeled nucleotide moiety of formula I or formula Γ , the oligonucleotide having a sequence complementary to that of the target nucleic acids; a denaturation reagent for converting double-stranded nucleic acid 60 to single-stranded nucleic acid; and a hybridization reaction mixture. The kit can also include a signal-generating system, such as an enzyme for example, and a substrate for the system.

65 The following examples are provided to illustrate the present invention without limiting same. "RT" means room temperature.

General

Thin layer chromatography was performed on silica gel 60 F 254 plates (Analtech) using the following solvent mixtures: A- 90% methylene chloride:10% methanol; B- 50% ethyl acetate:50% hexanes; C- 70% ethyl acetate: 10% methanol:10% water:10% acetone; D- 50% ether:50% hexanes. Flash chromatography was performed using 60 F 254 silica (Merck). Oligonucleotides were synthesized on an Applied Biosystems Model 380B Synthesizer. Oligonucleotides were isotopically labeled using T4 Polynucleotide kinase (BRL) and τ -³²P-ATP (New England Nuclear).

EXAMPLE 1

6-(Tritylamo)caproic Acid

15

6-Aminocaproic acid (26 g. 0.2 mole) was dissolved in dichloromethane (200 mL) by the addition of triethylamine (100 mL). Trityl chloride (120 g. 0.45 mole) was added and the solution stirred for 36 hr. The resulting solution was extracted with 1N HCl and the organic layer evaporated to dryness. The residue was suspended in 2-propanol/1N NaOH (300 mL/100 mL) and refluxed for 3 hr. The solution was evaporated to a thick syrup and added to dichloromethane (500 mL). Water was added and acidified. The phases were separated, and the organic layer dried over sodium sulfate and evaporated to dryness. The residue was suspended in hot 2-propanol, cooled, and filtered to give 43.5 g (58%) of 6-(trityl-amino)caproic acid, useful as an intermediate compound.

20

EXAMPLE 2

5-(Tritylamo)

pentylhydroxymethylenemalononitrile

To a dichloromethane solution of 6-(tritylamo)-caproic acid (20.0 g. 53 mmole) and triethylamine (20 mL) in an ice bath was added dropwise over 30 min isobutyl-chloroformate (8.3 mL. 64 mmole). After the mixture was stirred for 2 hr in an ice bath, freshly distilled malononitrile (4.2 g. 64 mmole) was added all at once. The solution was stirred for 2 hr in an ice bath and for 2 hr at RT. The dichloromethane solution was washed with ice cold 2N HCl (300 mL) and the biphasic mixture was filtered to remove product that precipitated (13.2 g). The phases were separated and the organic layer dried and evaporated to a thick syrup. The syrup was covered with dichloromethane and on standing deposited fine crystals of product. The crystals were filtered and dried to give 6.3 g for a total yield of 19.5 g (87%) of the product, which is useful as an intermediate.

30

EXAMPLE 3

5-(Tritylamo)

pentylmethoxymethylenemalononitrile

A suspension of the malononitrile of Example 2 (13 g. 31 mmole) in ether/dichloromethane (900 mL/100 mL), cooled in an ice bath, was treated with a freshly prepared ethereal solution of diazomethane (from 50 mmole of Diazald® (Aldrich Chemical Company)). The solution was stirred for 6 hr and then neutralized with acetic acid (10 mL). The solution was evaporated to dryness and the residue chromatographed on silica gel using dichloromethane/acetone (4/1) as the eluent. Fractions containing product were pooled and evaporated to a syrup. The syrup was triturated with dichloromethane to induce crystallization. The crystals were filtered and dried to give 8.3 g (61%) of chromatographically pure product, useful as an intermediate compound.

40

45

50

55

60

65

18
EXAMPLE 4

5-Amino-3-[(5-tritylamo)pentyl]pyrazole-4-carbonitrile

5 To a methanol solution (100 mL) of the product of Example 3 (7.0 g, 16 mmole) in an ice bath was added hydrazine monohydrate (7.8 mL, 160 mmole) dropwise over 15 min. After stirring for 30 min in an ice bath, the solution was evaporated to dryness. The residue was suspended in 10 cold methanol and filtered to give 7.1 g (100%) of 5-amino-3-[(5-tritylamo)pentyl]pyrazole-4-carbonitrile, useful as an intermediate, after drying. An analytical sample was prepared by recrystallization from water.

15 EXAMPLE 5

5-Amino-1-(2-deoxy-3,5-di-O-toloyl- β -D-erythropentofuranosyl)-3-[(5-tritylamo)pentyl]pyrazole-4-carbonitrile

20 An ice cold solution of the carbonitrile from Example 4 (3.5 g, 8 mmole) was treated with sodium hydride and stirred for 30 min at 0°-4° C. 1-Chloro-1,2-dideoxy-3,5-di-O-toloylribofuranose was added and the solution stirred for 1 hr at 0°-4° C. The solution was poured into a saturated 25 solution of sodium bicarbonate and extracted with dichloromethane. The organic layer was dried over sodium sulfate and evaporated to dryness. The residue was flash chromatographed on silica gel using toluene/ethyl acetate (5/1) as eluent. Two major products were isolated and identified as 30 the N-1 and N-2 isomers in 57% (3.6 g) and 20% (1.2 g) N-1 and N-2 yields, respectively. Approximately 1 g of a mixture of N-1 and N-2 isomers was also collected. Overall yield of glycosylated material was 5.8 g (92%). The N-1 isomer, 35 5-amino-1-(2-deoxy-3,5-di-O-toloyl- β -D-erythropentofuranosyl)-3-[(5-tritylamo)pentyl]pyrazole-4-carbonitrile, was used without further purification in Example 6.

EXAMPLE 6

40 1-(2-Deoxy- β -D-erythropentofuranosyl)-3-[5-(tritylamo)-pentyl]pyrazolo[3,4-d]pyrimidin-4-amine

To a toluene (100 mL) solution of the pyrazole-4-carbonitrile of Example 5 (3.5 g, 4.4 mmole) was added diethoxymethyl acetate (1.1 mL, 6.7 mmole). The solution was kept at 80°-90° C. for 5 hr and then evaporated to a syrup. The syrup was dissolved in dichloromethane (10 mL) and added to ice cold methanolic ammonia (100 mL) in a 50 glass pressure bottle. After two days at RT the contents of the bottle were evaporated to dryness. The residue was dissolved in methanol and adjusted to pH 8 with freshly prepared sodium methoxide to complete the deprotection. After stirring overnight the solution was treated with 55 Dowex®-50 H⁺ resin, filtered, and evaporated to dryness. The residue was chromatographed on silica gel using acetone/hexane (3/2) as eluent to give 2.0 g (77%) of analytically pure product.

60 EXAMPLE 7

1-(2-Deoxy- β -

• D-erythropentofuranosyl)-3-[5-(tritylamo)-pentyl]pyrazolo[3,4-d]pyrimidin-4-amine 5'-monophosphate

65 To an ice cold solution of the pyrazolopyrimidin-4-amine of Example 6 (250 mg, 0.43 mmole) in trimethyl phosphate

19

(5 mL) was added phosphoryl chloride (50 μ L) and the solution was kept at 0°-4° C. The reaction was monitored by reversed phase HPLC using a linear gradient from 0 to 100% acetonitrile in water over 25 min. After stirring for 5 hr, an additional aliquot of phosphoryl chloride (25 μ L) was added ⁵ and the solution was stirred another 30 min. The solution was poured into 0.1M ammonium bicarbonate and kept in the cold overnight. The solution was then extracted with ether and the aqueous layer evaporated to dryness. The residue was dissolved in water (5 mL) and purified by ¹⁰ reversed phase HPLC using a 22mm \times 50cm C18 column. The column was equilibrated in water and eluted with a gradient of 0 to 100% acetonitrile over 20 min. Fractions containing the desired material were pooled and lyophilized to give 160 mg (56%) of chromatographically pure nucle- ¹⁵ ootide.

EXAMPLE 8

1-(2-Deoxy- β -D-erythropentofuranosyl)-3-[5-(6-biotinamido)-hexanamido]pentyl]pyrazolo[3,4-d]pyrimidin-4-amine 5'-monophosphate. ²⁰

An ethanol solution (10 mL) of the nucleotide of Example 7, palladium hydroxide on carbon (50 mg), and cyclohexadiene (1 mL) was refluxed for 3 days, filtered, and evaporated to dryness. The residue was washed with dichloromethane, dissolved in DMF (1.5 mL) containing triethylamine (100 mL), and treated with N-hydroxysuccinimidyl biotinylaminocaproate (50 mg). After stirring overnight an additional amount of N-hydroxysuccinimidyl 6-biotinamidocaproate (50 mg) was added and the solution was stirred for 18 hr. The reaction mixture was evaporated to dryness and chromatographed following the procedure in Example 7. Fractions were pooled and lyophilized to give 80 mg of chromatographically pure biotinamido-substituted ²⁵ nucleotide. ³⁰ ³⁵

EXAMPLE 9

1-(2-Deoxy- β -D-erythropentofuranosyl)-3-[5-(6-biotinamido)-hexanamidopentyl]pyrazolo[3,4-d]pyrimidin-4-amine 5'-triphosphate. ⁴⁰

The monophosphate of Example 8 (80 mg, ca. 0.1 mmole) ⁴⁵ was dissolved in DMF with the addition of triethylamine (14 μ L). Carbonyldiimidazole (81 mg, 0.5 mmole) was added and the solution stirred at RT for 18 hr. The solution was treated with methanol (40 μ L), and after stirring for 30 min tributylammonium pyrophosphate (0.5 g in 0.5 mL DMF) ⁵⁰ was added. After stirring for 24 hr another aliquot of tributylammonium pyrophosphate was added and the solution was stirred overnight. The reaction mixture was evaporated to dryness and chromatographed following the procedure in Example 8. Two products were collected and were ⁵⁵ each separately treated with conc. ammonium hydroxide (1 mL) for 18 hr at 55° C. UV and HPLC analysis indicated that both products were identical after ammonia treatment and were pooled and lyophilized to give 35.2 mg of nucleoside triphosphate. ⁶⁰

EXAMPLE 10

Nick-Translation Reaction

The triphosphate of Example 9 was incorporated into ⁶⁵ pHPV-16 using the nick translation protocol of Langer et al. (supra). The probe prepared with the triphosphate of

Example 9 was compared with probe prepared using commercially available bio-11-dUTP (Sigma Chemical Co). No significant differences could be observed in both a filter hybridization and in *in situ* smears.

5 More specifically, the procedure involved the following materials and steps:

Materials:

DNase (ICN Biomedicals)-4 µg/mL

10 DNA polymerase 1 (U.S. Biochemicals)-8 U/mL

pHPV-16-2.16 mg/mL which is a plasmid containing the genomic sequence of human papillomavirus type 16.

15 10X-DP-1M Tris, pH 7.5 (20 mL); 0.5M DTT (80 mL); 1M MgCl₂ (2.8 mL); H₂O (17 mL)

15 Nucleotides-Mix A-2 mM each dGTP, dCTP, TTP (Pharmacia)

Mix U-2 mM each dGTP, dCTP, dATP

Bio-11-dUTP-1.0 mg/mL (BRL)

Bio-12-dAPTP-1.0 mg/mL

20 Steps:

To an ice cold mixture of 10X-DP (4 mL), pHPV-16 (2 mL), nucleotide mix A (6 mL), Bio-12-dAPTP (2 mL), and H₂O (20 mL) was added DNase (1 mL) and DNA polymerase 1 (2.4 mL). The reaction mixture was incubated at 25 16° C. for 1 hr. The procedure was repeated using Bio-11-dUTP and nucleotide mix U in place of Bio-12-dAPTP (comprising the triphosphate of Example 9) and nucleotide mix A.

30 Nucleic acid was isolated by ethanol precipitation and hybridized to pHPV-16 slotted onto nitrocellulose. The hybridized biotinylated probe was visualized by a streptavidin-alkaline phosphatase conjugate with BCIP/NBT substrate. Probe prepared using either biotinylated nucleotide gave identical signals. The probes were also 35 tested in an *in situ* format on cervical smears and showed no qualitative differences in signal and background.

EXAMPLE 11

40 5-Amino-3-[(5-tritylamo)pentyl]pyrazole-4-carboxamide

Following the procedure of Example 2, except that 45 cyanooacetamide is used instead of malononitrile, 5-(tritylamo)pentylhydroxymethylenecyanoacetamide is prepared from 6-(tritylamo)caproic acid. This is then treated with diazomethane to give the methoxy derivative, following the procedures of Example 3, which is then reacted with hydrazine monohydrate, as in Example 4, to give 5-amino-3-[(5-tritylamo)pentyl]pyrazole-4-carboxamide.

50

EXAMPLE 12

4-Hydroxy-6-methylthio-3-[(5-tritylamo)pentyl]pyrazolo-[3,4-d]pyrimidine.

55 The carboxamide from Example 11 is reacted with potassium ethyl xanthate and ethanol at an elevated temperature to give the potassium salt of 4-hydroxypyrazolo[3,4-d]pyrimidine-6-thiol. This salt is then reacted with iodomethane to give 4-hydroxy-6-methylthio-3-[(5-tritylamo)pentyl]pyrazolo[3,4-d]pyrimidine.

60

EXAMPLE 13

1-(2-Deoxy- β -D-crythropentofuranosyl)-4-hydroxy-3-[(5-tritylamo)pentyl]pyrazolo[3,4-d]pyrimidin-6-amine

65 Following the procedure of Example 5, the pyrazolopyrimidine of Example 12 is treated with sodium hydride and

reacted with 1-chloro-1,2-dideoxy-3,5-di-Q-toluoylribofuranose. The resulting compound is reacted with MCPBA and with methanolic ammonia, and the toluoyl protecting groups are removed to give the product.

EXAMPLE 14

5

1-(2-Deoxy- β -D-erythropentofuranosyl)-4-hydroxy-3-[5-(6-biotin amido)hexanamidopentyl]pyrazolo[3.4-d]pyrimidin-6-amine 10 5'-monophosphate.

Following the procedure of Example 7, the pyrazolopyrimidine of Example 13 is reacted with phosphoryl chloride to give the corresponding 5'-monophosphate.

Following the procedure of Example 8, the above 5'-monophosphate is reacted with palladium/carbon and cyclohexadiene, and the residue is reacted with N-hydroxysuccinimidyl biotinylaminocaproate to give 1-(2-deoxy- β -D-erythropentofuranosyl)-4-hydroxy-3-[5-(6-biotin amido)hexanamidopentyl]pyrazolo[3.4-d]pyrimidin-6-amine 20 5'-monophosphate.

EXAMPLE 15

1-(2-Deoxy- β -D-erythropentofuranosyl)-4-hydroxy-3-[5-(6-biotin amido)hexanamidopentyl]pyrazolo[3.4-d]pyrimidin-6-amine 25 5'-triphosphate

Following the procedure of Example 9, the 5'-monophosphate of Example 14 is treated with carbonyldiimidazole and then reacted with tributylammonium pyrophosphate to give the corresponding 5'-triphosphate.

EXAMPLE 16

1-(2-Deoxy- β -D-erythropentofuranosyl)-3-[5-(tritylamo)-pentyl]pyrazolo[3.4-d]pyrimidine-4-benzoylamine 35
1 - (2 - D e o x y - β - D-erythropentofuranosyl)-3-[5-(tritylamo)pentyl]pyrazolo[3.4-d]pyrimidine-4-amine from Example 6 is reacted with benzoyl chloride and pyridine to give 1-(2-deoxy-3,5-di-Q-benzoyl- β -D-erythro-pentofuranosyl)-3-[5-(tritylamo)pentyl]pyrazolo[3.4-d]pyrimidine-4-dibenzoylamine. This is treated with aqueous sodium hydroxide to partially deprotect the compound, giving 1-(2-deoxy- β -D-erythropentofuranosyl)-3-[5-(tritylamo)pentyl]pyrazolo[3.4-d]pyrimidine-4-benzoylamine.

EXAMPLE 17

1-(2-Deoxy- β -D-erythropentofuranosyl)-3-[5-(trifluoroacetamido)pentyl]pyrazolo[3.4-d]pyrimidine-4-benzoylamine 50

Following the procedure of Example 8, the benzoylamine of Example 16 is treated with palladium hydroxide on carbon and then with trifluoroacetic anhydride to give 1-(2-deoxy- β -D-erythropentofuranosyl)-3-[5-(trifluoroacetamido)pentyl]pyrazolo[3.4-d]pyrimidine-4-benzoylamine.

EXAMPLE 18

60

1-(2-Deoxy-5-Q-dimethoxytrityl- β -D-erythropentofuranosyl)-3-[5-(trifluoroacetamido)pentyl]pyrazolo[3.4-d]pyrimidine-4-benzoylamine 65 3'-Q-(N,N-diisopropyl)phosphoramidite cyanoethyl ester

The compound of Example 17 is reacted with dimethoxytrityl chloride and pyridine to give the corresponding

5'-dimethoxytrityl compound. This compound is then reacted with cyanoethyl chloro-N,N-diisopropyl-phosphoramidite (according to the method of Sisha et al., *Nucleic Acids Res.*, 12:4539 (1984)) to give the 3'-Q-activated nucleoside.

EXAMPLE 19

5-(4-Phthalimidobut-1-yn-1-yl)-2'-deoxyuridine

10 5-Iodo-2'-deoxyuridine (354 mg, 1 mmol) was dissolved in 10 mL of dimethylformamide. Cuprous iodide (76 mg, 0.4 mmol), tetrakis(triphenylphosphine)palladium(0) (230 mg, 0.2 mmol), and triethylamine (200 mg, 2.0 mmol) were added. 4-Phthalimidobut-1-yne (300 mg, 1.5 mmol) was 15 added all at once and the reaction kept at 60° C. for three hours. The clear yellow reaction was then evaporated and methylene chloride was added. Scratching of the flask induced crystallization of nearly all of the product which was filtered and recrystallized from 95% ethanol to give 335 20 mg (78%) of title compound as fine, feathery needles.

EXAMPLE 20

5-(4-Phthalimidobut-1-yl)-2'-deoxyuridine

25 1.00 Gram of deoxyuridine from Example 19 was dissolved in 95% EtOH and about 3 g of neutral Raney nickel was added. After 48 hours, the catalyst was removed by 30 cautious filtration and the filtrate was evaporated to a solid which was recrystallized from methanol-water to give 960 mg (97%) of the title compound.

EXAMPLE 21

5-(3-Iodoacetamidopropyl)-2'-deoxyuridine

35 5-(3-Trifluoroacetamidoprop-1-yl)-2'-deoxyuridine (0.3 mmol) is treated with ammonia and then with N-hydroxysuccinimidyl α -iodoacetate (0.5 mmol). The reaction mixture is evaporated to dryness and purified by chromatography to give 5-(3-iodoacetamidopropyl)-2'-deoxyuridine.

EXAMPLE 22

5-(4-(4-Bromobutyramido)butyl)-2'-deoxyuridine

45 Following the procedure of Example 21, 5-(4-phthalimidobut-1-yl)-2'-deoxyuridine, from Example 20, is treated with ammonia and then with N-hydroxysuccinimidyl 4-bromobutyrate to give 5-(4-(4-bromobutyramido)butyl)-50 2'-deoxyuridine.

50 Preparation of Synthetic Oligonucleotides

EXAMPLE 23

Phosphoramidite Preparation and DNA Synthesis

55 Nucleosides were 5'-dimethoxytritylated, following known procedures, to give around 85% yield, and the 3'-phosphoramidite was made using diisopropylamino β -cyanoethylchlorophosphite (as described in "Oligonucleotide Synthesis: A Practical Approach", *supra*) with diisopropyl-ethylamine in methylene chloride. The phosphoramidite was made into a 0.2N solution in acetonitrile and placed on the automated DNA synthesizer. Incorporation of these new and modified phosphoramidites gave 60 incorporation similar to ordinary phosphoramidites 65 (97-99% as judged by assay of the trityl color released by UV.)

Oligonucleotides were removed from the DNA synthesizer in tritylated form and deblocked using 30% ammonia at 55° C. for 6 hours. Ten μ L of 0.5M sodium bicarbonate was added to prevent acidification during concentration. The oligonucleotide was evaporated to dryness under vacuum 5 and redissolved in 1.0 mL water. The oligonucleotides were purified by HPLC using 15-55% acetonitrile in 0.1N triethylammonium acetate over 20 minutes. Unsubstituted oligonucleotides came off at 10 minutes; amino derivatives took 11-12 minutes. The desired oligonucleotide was collected and evaporated to dryness, then it was redissolved in 80% aqueous acetic acid for 90 minutes to remove the trityl group. Desalting was accomplished with a G25 Sephadex column and appropriate fractions were taken. The fractions were concentrated, brought to a specific volume, dilution 15 reading taken to ascertain overall yield and an analytical HPLC done to assure purity. oligonucleotides were frozen at -20° C. until use.

Following the above procedures, the nucleoside 5-(3-trifluoroacetamidoprop-1-yl)-2'-deoxyuridine was converted to the 5'-O-dimethoxytrityl-3'-(N,N-diisopropyl)-phosphoramidite cyanoethyl ester derivative. This was added to a DNA synthesizer and the following 14-mer oligonucleotide sequence was prepared:

25
3'-CT TCC U¹TG TAG GTC-5'

where U¹ is 5-(3-aminoprop-1-yl)-2'-deoxyuridine (oligo A).

In the same manner, 5-(4-phthalimidobut-1-yl)-2'-deoxyuridine was converted to the 5'-O-dimethoxytrityl-3'-(N,N-diisopropyl)phosphoramidite cyanoethyl ester derivative and added to a DNA synthesizer to prepare the above 14-mer oligonucleotide sequence where U¹ is 5-(4-aminobut-1-yl)-2'-deoxyuridine (oligo C).

A corresponding 14-mer oligonucleotide was also prepared where U¹ is the unmodified deoxyuridine.

EXAMPLE 24

Derivatization of Oligonucleotides

40

In general, to add the crosslinking arm to an aminoalkyloligonucleotide, a solution of 10 μ g of the aminoalkyloligonucleotide and a 100X molar excess of α -hydroxysuccinimide haloacylate such as α -haloacetate or 45 4-halobutyrate in 10 μ L of 0.1M borate buffer, pH 8.5, was incubated at ambient temperature for 30 min. in the dark. The entire reaction was passed over a NAP-10 column equilibrated with and eluted with distilled water. Appropriate fractions based on UV absorbance were combined and 50 the concentration was determined spectrophotometrically.

Introduction of the haloacyl moiety was examined by HPLC. A Zorbax[®] oligonucleotide column (Dupont) eluted with a 20 minute gradient of 60% to 80% B composed of: A (20% acetonitrile:80% 0.02 N NaH₂PO₄) and B (1.2 N 55 NaCl in 20% acetonitrile:80% 0.02 N NaH₂PO₄). The presence of a reactive α -haloacyl moiety was indicated by return of the retention time of the α -haloacylamidoalkyl oligonucleotide to the corresponding aminoalkyl oligonucleotide after exposure to 1N cysteamine. Introduction of 60 cysteamine created equivalent charge patterns between the aminoalkyl oligonucleotide and the α -haloacylamido oligonucleotide.

Following the above procedure, the 14-mer oligonucleotide:

65

3'-CT TCC U¹TG TAG GTC-5'

where U¹ is 5-(3-aminoprop-1-yl)-2'-deoxyuridine (oligo A. Example 23). was reacted with α -hydroxysuccinimide α -iodoacetate to give the above 14-mer oligonucleotide where U¹ is 5-(3-iodoacetamidoprop-1-yl)-2'-deoxyuridine 5 (oligo B).

Oligo A and oligo B, as well as the above 14-mer where U¹ is the unmodified deoxyuridine were resolved in the Zorbax column, all of identical sequence, with the following retention times: unmodified 14-mer 9.31 min; aminopropyl 10 14-mer (oligo A). 7.36 min; and iodoacetamido-propyl 14-mer (oligo B). 10.09 min.

In the same manner, the aminopropyl 14-mer (oligo A) was reacted with N-hydroxysuccinimide 4-bromobutyrate to give the 14-mer where U¹ is 5-(3-(4-bromobutyramido) 15 prop-1-yl)-2'-deoxyuridine.

Also, the aminobutyl 14-mer (oligo C. Example 23) was reacted with either N-hydroxysuccinimide α -iodoacetate or N-hydroxysuccinimide 4-bromobutyrate to give the 14-mer where U¹ is 5-(4-iodoacetamidobut-1-yl)-2'-deoxyuridine or 20 5-(4-(4-bromobutyramido)but-1-yl)-2'-deoxyuridine, respectively.

Assays

EXAMPLE 25

25

Assay of Crosslinking Reaction

The reaction of crosslinking a DNA probe to a target nucleic acid sequence contained 1 μ g of haloacylamidoalkyl probe and 10 ng of 32 P-labeled cordycepin-tailed 30 target in 200 μ L of 0.1M Tris, pH 8.0, and 0.9M NaCl incubated at 20° or 30° C. Aliquots were removed at 24- or 72-hour intervals and diluted in 20 μ L of 10 mM cysteamine to quench the haloacylamido group. These solutions were stored at RT, and 1 μ L was used for analysis by denaturing 35 polyacrylamide gel electrophoresis (PAGE).

Following the above procedure, two model oligonucleotide sequences were utilized to evaluate the crosslinkage potential of the modified probe to its complement. The 40 sequences, derived from human papilloma-virus (HPV) or human cytomegalovirus (CMV), are shown below:

HPV System:
5 10 15 20 25 30
45 Target: 5'-AGA CAG CAC AGA ATT CGA AGG AAC ATC CAG-3'
Probe: 3' - CT TCC UTG TAG GCT-5'

CMV System:
5 10 15 20
50 Target: 5'-ACC GTC CTT GAC ACG ATG GAC TCC-3'
Probe: 3' - GAA CTG TGC UAC CTC-5'

55 U = 5-(3-(α -iodoacetamido)- or 3-(4-bromobutyramido)-propyl)-2'-deoxyuridine, or
U = 5-(3-(α -iodoacetamido)- or 4-(4-bromobutyramido)-butyl)-2'-deoxyuridine.

The target for HPV is a 30-mer, and for CMV it is a 24-mer. The crosslinking probes were a 14-mer for HPV and two 15-mers for CMV. Each probe contained a single 60 modified deoxyuridine designated as U in the sequences above.

Results of the reaction of HPV target with a limiting amount of crosslinking probe containing a 5-(3-iodoacetamidopropyl) sidearm are shown in FIG. 2. Analysis of the cleavage pattern on a denaturing PAGE gel showed the loss of the crosslinked hybrid with the concomitant appearance of a discrete low molecular weight band. The 65

intensity of this band was dependent upon the extent of crosslinkage in the initial reaction. The localization of signal into two discrete bands on the gel strongly argues that no non-sequence-directed alkylation of either target or probe strands had occurred (including intramolecular probe 5 alkylation).

Comparison to an authentic 15-mer run in an adjacent lane suggested that the major cleaved fragment is a 9-mer. Upon close examination of the original autoradiogram, a slower moving band of very weak intensity was visible. This 10 pattern would be consistent with major alkylation at G-21 and minor alkylation at G-20. An examination of a Dreiding model of the crosslinkable HPV hybrid shows that the 5-(3-iodoacetamidopropyl) sidearm can contact the G-21 residue of the target strand with only minor distortion of the 15 helix.

If alkylation occurs predominately at a guanosine on the target strand located two units on the 5' side of the modified-deoxyuridine base pair, the CMV sequence should not react. 20 This result was in fact observed. The absence of reaction with CMV further supports the specificity of crosslinking scheme of the invention.

EXAMPLE 26

25

Time and Temperature Dependence

Time and temperature dependence studies were carried out with the HPV system of Example 25 where U is 5-(3-iodoacetamidoprop-1-yl)-2'-deoxyuridine. The target 30 was ^{32}P -labeled by cordycepin tailing with terminal transferase (Maniatis et al. "Molecular Cloning—A Laboratory Manual", Cold Spring Harbor Laboratory, 1982, p. 239) and incubated with excess probe in a pH 8.0 Tris buffer at either 20° or 30° C. Aliquots were removed after 0, 24, or 72 hours

SEQUENC

(1) GENERAL INFORMATION:

(i i i) NUMBER OF SEQUENCES: 5

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(i x) FEATURE:

- (A) NAME/KEY: modified_base
- (B) LOCATION: 9
- (D) OTHER INFORMATION: /note= "U may be 5-(3- aminoprop-1-yl)-2'-deoxyuridine"

(i x) FEATURE:

- (A) NAME/KEY: modified_base
- (B) LOCATION: 9
- (D) OTHER INFORMATION: /note= "U may be 5-(4- aminobut-1-yl)-2'-deoxyuridine"

(i x) FEATURE:

- (A) NAME/KEY: modified_base
- (B) LOCATION: 9
- (D) OTHER INFORMATION: /note= "U may be the unmodified deoxyuridine"

(i x) FEATURE:

- (A) NAME/KEY: modified_base

incubation, quenched with an equivalent volume of 10 mM mercaptoethylamine (which reacts with the iodoacetamide), and stored at RT for subsequent analysis by denaturing or non-denaturing PAGE.

5 Crosslinkage of the hybrid, which was monitored by denaturing PAGE, was evident for the 24 and 72 hour time points at both temperatures (see FIG. 3). The amount of crosslinked hybrid increased with both temperature and time. Approximately 20% of the hybrid was crosslinked
10 after 72 hours incubation at 30° C.

Separate experiments at a range of temperatures indicated that the half-life for crosslinking at 37° C. is approximately 2 days, and that the reaction is complete after 24 hours at 58° C. This time-dependent reaction implies that the iodoacetamido moiety does not hydrolyze or react with the buffer. The
15 increased reaction rate at higher temperature indicates that the hybrid is maintained, and subsequently the rate of alkylation shows the expected increase with temperature.

20

EXAMPLE 27

Site Specificity of Alkylation

To elucidate the site specificity of alkylation, the
25 crosslinked HPV hybrid of Example 25 (where U is 5-(3-iodoacetamidoprop-1-yl)-2'-deoxyuridine) was subjected to a 10% piperidine solution at 90° C. for 60 minutes. As shown by Maxam et al. (*Proc. Natl. Acad. Sci. USA*, 74: 560 (1977)), this treatment quantitatively cleaves the target strand
30 3'-to the site of alkylation. The resulting data indicated that the alkylation of the second guanine above the crosslinker-modified base pair (i.e., the guanine above the target base) was the exclusive action observed, indicating that the crosslinking reaction in the HPV model system is remarkably specific.

-continue-

(B) LOCATION: 9
(D) OTHER INFORMATION: /note= "U may be
5-(3- iodoacetamido-prop-1-yl)-2'-deoxyuridine"

(i x) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 9
(D) OTHER INFORMATION: /note= "U may be
5-(3-(4- bromobutyramido)prop-1-yl)-2'-deoxyuridine
e"

(i x) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 9
(D) OTHER INFORMATION: /note= "U may be
5-(4- iodoacetamido-but-1-yl)-2'-deoxyuridine"

(i x) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 9
(D) OTHER INFORMATION: /note= "U may be
5-(4- (4- bromobutyramido)but-1-yl)-2'-deoxyuridine"

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CTGGATGTUC CTTC

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AGACAGCACA GAATTCTGAAG GAACATCCAG

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(i x) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 9
(D) OTHER INFORMATION: /note= "U may be
5-(3- (alpha- iodoacetamido)-propyl)-2'-deoxyuridine
e"

(i x) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 9
(D) OTHER INFORMATION: /note= "U may be
5-(3- (bromobutyramido)-propyl)-2'-deoxyuridine"

(i x) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 9
(D) OTHER INFORMATION: /note= "U may be
5-(4-alpha- iodoacetamido)-butyl)-2'-deoxyuridine"

(i x) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 9
(D) OTHER INFORMATION: /note= "U may be
5-(4- (4- bromobutyramido)-butyl)-2'-deoxyuridine"

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CTGGATGTUC CTTC

(2) INFORMATION FOR SEQ ID NO:4:

Express Mail Label No.
EL008722715US

28

14

30

14

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ACCGTCCTTG ACACGATGGA CTCC

(2) INFORMATION FOR SEQ ID NO:5:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(i x) FEATURE:

- (A) NAME/KEY: modified_base
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /note= "U may be
5-[3-(alpha-iodoacetamido)-propyl]-2'-deoxyuridine"

(i x) FEATURE:

- (A) NAME/KEY: modified_base
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /note= "U may be
5-[3-(4-bromobutyramido)-propyl]-2'-deoxyuridine"

(i x) FEATURE:

- (A) NAME/KEY: modified_base
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /note= "U may be
5-[4-(alpha-iodoacetamido)-butyl]-2'-deoxyuridine"

(i x) FEATURE:

- (A) NAME/KEY: modified_base
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /note= "U may be
5-[4-(4-bromobutyramido)-butyl]-2'-deoxyuridine"


(x i) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CTCCAUUCGTG TCAAG

What is claimed is:

1. An oligonucleotide having at least one nucleotide of the formula

45



wherein

R_1 is a 1-(β -D-ribofuranosyl) or 1-(β -D-2-deoxyribofuranosyl) group which is optionally substituted on one or more of its hydroxyl functions with a Z group, wherein Z independently is methyl or a phosphate, thiophosphate, alkylphosphate or alkane-phosphonate group;

50

B is a heterocyclic base selected from purine and pyrazolo[3.4-d]pyrimidine groups wherein the $(CH_2)_q$ group is attached to the 7-position or 8 position of the purine and 3-position of the pyrazolo[3.4-d]pyrimidine groups and the R_1 group is attached to the 9-position of the purine and to the 1-position of the pyrazolo[3.4-d]pyrimidine groups;

55

Y is a functional linking group selected from a group consisting of $-O-$, $-S-$, $-NR'-$, $-NH-CO-$, trifluoroacetamido and phthalimido groups where R' is H or C_{1-6} alkyl, and at least one of the $(CH_2)_m$ and $(CH_2)_q$ groups is directly linked to the $-O-$, $-S-$.

60

65

—NR'—, NH—CO—, trifluoroacetamido and phthalimido groups and the other of said $(CH_2)_m$ and $(CH_2)_q$ groups is linked to the heterocyclic base with a carbon to carbon bond;

45 m is 1 to 8, inclusive;

q is 0 to 8, inclusive;

r is 0 or 1; and

50 A' is a group selected from chloro, bromo, iodo, SO_2R' , $S^*R''R'''$ and a radical which activates the carbon to which it is attached for nucleophilic substitution, where each of R' and R''' is independently C_{1-6} alkyl or aryl or R'' and R''' together form a C_{1-6} alkylene bridge.

55 2. An oligonucleotide according to claim 1 wherein B is selected from adenine-8-yl, guanine-8-yl, 4-aminopyrazolo[3,4-d]pyrimidin-3-yl, and 4-amino-6-oxopyrazolo[3,4-d]pyrimidin-3-yl groups.

3. An oligonucleotide according to claim 1 wherein m is 1, 2 or 3; q is 2, 3, or 4; and r is 1.

60 4. An oligonucleotide according to claim 1 wherein the R₁ group is 1-(β -D-ribofuranosyl).


5. An oligonucleotide according to claim 1 wherein the R₁ group is 1-(β -D-2-deoxyribofuranosyl).

6. An oligonucleotide according to claim 1 wherein the R₁ group is 1-(β -D-2-O-methyl-ribofuranosyl).

65 7. An oligonucleotide according to claim 1 wherein the group $—(CH_2)_q—(Y)—(CH_2)_m—A'$ is

3-iodoacetamidopropyl, 3-(4-bromobutyramido)propyl,
4-iodoacetamidobutyl, or 4-(4-bromobutyramido)butyl.

8. A compound of the formula



5

10

where R_1 is H, or a 1-(β -D-ribofuranosyl) or 1-(β -D-2-deoxyribofuranosyl) group which is optionally substituted on one or more of its hydroxyl functions with a Z group wherein Z independently is methyl or a phosphate, thiophosphate, alkylphosphate or alkane-phosphonate group, or a reactive precursor of said phosphate, thiophosphate, alkylphosphate or alkane-phosphonate group which precursor is suitable for 20 internucleotide bond formation;

R_3 is $(CH_2)_q-(Y)--(CH_2)_m-A''$ where A'' is a group selected from chloro, bromo, iodo, SO_2R'' , $S'R''R'''$ and a radical which activates the carbon to which it is attached for nucleophilic substitution, where each of R'' and R''' is independently C_{1-6} alkyl or aryl or R'' and R''' together form a C_{1-6} alkylene bridge, or A'' is an intercalator group, a metal ion chelator or a reporter group;


Y is a functional linking group selected from a group consisting of $-O-$, $-S-$, $-NR'-$, $-NH-CO-$, trifluoroacetamido and phtalimido groups where R' is H or C_{1-6} alkyl, and at least one of the $(CH_2)_m$ and $(CH_2)_q$ groups is directly linked to said $-O-$, $-S-$, $-NR'-$, $NH-CO-$, trifluoroacetamido and phtalimido groups and the other of said $(CH_2)_m$ and $(CH_2)_q$ groups is linked to the heterocyclic base with a carbon to carbon bond;

each of m and q is independently 0 to 8, inclusive; r is 0 or 1 provided that when A'' is a group selected from chloro, bromo, iodo, SO_2R'' , $S'R''R'''$ and a radical which activates the carbon to which it is attached for nucleophilic substitution, then m is not 0;

each of R_4 and R_5 is independently H, OR, SR, NHOR, NH_2 , or $NH(CH_2)_tNH_2$ where R is H or C_{1-6} alkyl and t is an integer from 0 to 12.

9. A compound in accordance with claim 8 where each of R_4 and R_5 is independently selected from a group consisting of H, OH and NH_2 .

10. A compound of the formula



55

60

where R_1 is H, or a 1-(β -D-ribofuranosyl) or 1-(β -D-deoxyribofuranosyl) group which is optionally substituted on one or more of its hydroxyl functions with a Z group wherein Z independently is methyl or a phosphate, thiophosphate, alkylphosphate or alkane-phosphonate group, or a reactive precursor of said 65 phosphate, thiophosphate, alkylphosphate or alkane-phosphonate group.

phosphate, thiophosphate, alkylphosphate or alkane-phosphonate group which precursor is suitable for internucleotide bond formation;

5 R₃ is (CH₂)_q—(Y)_r—(CH₂)_m—A" and A" is a reporter group;

10 Y is a functional linking group selected from a group consisting of —O—, —S—, —NR'—, —NH—CO—, trifluoroacetamido and phtalimido groups where R' is H or C₁₋₆ alkyl, and at least one of the (CH₂)_m and (CH₂)_q groups is directly linked to said —O—, —S—, —NR'—, —NH—CO—, trifluoroacetamido and phtalimido groups and the other of said (CH₂)_m and (CH₂)_q groups is linked to the heterocyclic base with a carbon to carbon bond;


15 each of m and q is independently 0 to 8, inclusive; r is 0 or 1, and

each of R₄ and R₆ is independently H, OR, SR, NHOR, NH₂, or NH(CH₂)_tNH₂ where R is H or C₁₋₆ alkyl and 20 t is an integer from 0 to 12.

11. A compound in accordance with claim 10, where each of R₄ and R₆ is independently selected from a group consisting of H, OH and NH₂.

12. A compound in accordance with claim 11 where the 25 reporter group is biotin or 2,4-dinitrobenzene.

13. An oligonucleotide having at least one nucleotide of the formula



40 wherein R₁ is a 1-(β-D-ribofuranosyl) or 1-(β-D-2-deoxyribofuranosyl) group which is optionally substituted on one or more of its hydroxyl functions with a Z group wherein Z independently is methyl or a phosphate, thiophosphate, alkylphosphate or alkane-phosphonate group;

45 R₃ is (CH₂)_q—(Y)_r—(CH₂)_m—A and A is a reporter group;

50 Y is a functional linking group selected from a group consisting of —O—, —S—, —NR'—, —NH—CO—, trifluoroacetamido and phtalimido groups where R' is H or C₁₋₆ alkyl, and at least one of the (CH₂)_m and (CH₂)_q groups is directly linked to said —O—, —S—, —NR'—, —NH—CO—, trifluoroacetamido and phtalimido groups and the other of said (CH₂)_m and (CH₂)_q groups is linked to the heterocyclic base with a carbon to carbon bond;

55 each of m and q is independently 0 to 8, inclusive; r is 0 or 1, and

each of R₄ and R₆ is independently H, OR, SR, NHOR, NH₂, or NH(CH₂)_tNH₂ where R is H or C₁₋₆ alkyl and t is an integer from 0 to 12.

60 14. An oligonucleotide in accordance with claim 13 where each of R₄ and R₆ is independently selected from a group consisting of H, OH and NH₂.

65 15. An oligonucleotide in accordance with claim 14 where the reporter group is biotin or 2,4-dinitrobenzene.





Fig 1

Figure 2



32p-Labeled HPV Target

32p-Labeled 15-mer Marker

Minor Cleavage Product
Major Cleavage Product

1 2 3 4 5

Figure 3



Crosslinked Product

32p-Labelled HPV Target

Express Mail Label No. EL00822715US
Date of Deposit 10/19/00

PATENT
Attorney Docket No. 17682A-005100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:)
U.S. Patent No. 5,824,796)
Inventors: Charles R. Petrie, Rich B. Meyer,)
John C. Tabone and Gerald D. Hurst)
Serial No.: Not yet assigned) REISSUE DECLARATION UNDER
File: Herewith) 37 C.F.R. § 1.175(a) AND POWER OF
For: CROSS-LINKING) ATTORNEY
OLIGONUCLEOTIDES)
)
)

BOX REISSUE APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

We, Charles R. Petrie, Rich B. Meyer, John C. Tabone and Gerald D. Hurst declare as follows:

1. Charles R. Petrie of 18459 NW 196th Place, Woodinville, Washington 98072, Rich B. Meyer of 3739 Hamilton Way, Redwood City, California 94062, John C. Tabone of 12117 NE 166th Place, Bothell Washington 98011 and Gerald D. Hurst of *address unknown*, are citizens of the United States of America.

2. The entire right, title, and interest to U.S. Patent No. 5,824,796, issued October 20, 1998, is vested in Epoch Biosciences, Inc., a Delaware corporation, by assignment. Epoch Biosciences, Inc. has a regular and established place of business in Redmond, Washington 98052. An assignment from us to Microprobe Corporation (now Epoch Biosciences, Inc.) was recorded on October 26, 1988 at Reel 4963, Frame 220 for parent application Serial No. 250,474 and on July 24, 1989 at Reel 5162, Frame 48 for parent application Serial No. 353,857.

3. We are the original, first and joint inventors of the invention described and claimed in the above-identified United States Letters Patent and the claims added by the above referenced reissue application, for which invention we seek a reissue of the aforesaid Letters Patent.

4. We do not know and do not believe that said invention was ever known or used in the United States of America before our invention thereof.

5. We do not know and do not believe that said invention was in public use more than one year prior to filing the original application for U.S. Patent No. 5,824,796.

6. We do not know and do not believe that the invention was on sale, within the meaning of 35 USC 102(b), in this country more than one year prior to the filing date of said original application.

7. We also believe the original patent to be partly or wholly inoperative or invalid because of error without deceptive intent on our part. We believe the original patent to be partly or wholly inoperative or invalid because we claimed less than that to which we had a right to claim in the patent. In particular we believe that it was error not to include those compounds in which the linking groups between the nucleic acid bases and the reporter groups were unsaturated alkyl chains, such as for example, C₂-C₁₂ alkenylene and C₂-C₁₂ alkynylene in the original patent. New claims 16 through 44 are now added as reissue claims. The errors which resulted in this application for reissue and resulted in such claims not being included in the original patent arose due to our failure to appreciate the extent to which the original claims included elements which unduly limited the scope of protection afforded our invention. Our original patent claims, see claims 1-15, for example, contained claims to oligonucleotides and compounds in which crosslinking groups and reporter groups are attached to the oligonucleotide or compound via a saturated alkylene chain that is optionally interrupted by a heteroatom (e.g., O, NH or S). We believe we are also entitled to claims drawn to intermediates in the preparation of the claimed compounds that terminate in a heteroatom or protected form thereof.

8. More specifically, in the original application, we failed to recognize and appreciate features and combinations of the invention which we invented and which we believe are patentable over the prior art. We have added new claims 16-44 to other oligonucleotides and compounds of modified pyrazolo[3,4-d]pyrimidines and other pyrimidine bases to correct our error in not so claiming in our original patent. We believe this occurred in part because our preferred embodiment was the cross-linking oligonucleotides, and we failed to recognize that certain intermediates and other species of labeled compounds and oligonucleotides could be claimed.

9. We have reviewed and understand the contents of the attached specification and claims, including the new claims as presented in this application for reissue of the original Letters Patent.

10. We acknowledge the duty to disclose information of which we are aware and which is material to the examination of this application for reissue of the original Letters Patent in accordance with 37 C.F.R. § 1.56.

11. The aforementioned errors in claiming less than we had a right to claim arose without any deceptive intention on our part and was only recognized as a result of comparing the issued claims with the business interests of Epoch Pharmaceuticals, Inc., now Epoch Biosciences, Inc.

12. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

13. We hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: William M. Smith, Reg. No. 30,223, William B. Kezer, Reg. No. 37,369, Eugenia Garrett-Wackowski, Reg. No. 37,330, Joseph R. Snyder, Reg. No. 39,381 and Kevin L. Bastian, Reg. No. 34,774.

14. Please send all correspondence to Townsend and Townsend and Crew LLP, ATTN: William B. Kezer, Two Embarcadero Center, 8th Floor, San Francisco, California 94111-3834. Direct all telephone calls to Mr. Kezer at (415) 576-0200.

15. This declaration may be executed in counterpart and by copy with the same force and effect as if executed as one complete and integrated document.

Full name of first inventor: Charles R. Petrie

Inventor's signature: Charles R. Petrie 10/16/2000

Date: 10/16/2000 Country of Citizenship: U.S.A.

Residence: 18459 NW 196th Place, Woodinville, Washington 98072

Full name of second inventor: Rich B. Meyer

Inventor's signature: _____

Date: _____ Country of Citizenship: U.S.A.

Residence: 3739 Hamilton Way, Redwood, California 94062

Full name of third inventor: John C. Tabone

Inventor's signature: _____

Date: _____ Country of Citizenship: U.S.A.

Residence: 12117 NE 166th Place, Bothell Washington 98011

Full name of third inventor: Gerald D. Hurst

Inventor's signature: _____

Date: _____ Country of Citizenship: U.S.A.

Residence: *Unknown*

SF1142663

Express Mail Label No. EL00822715US
Date of Deposit 10/19/00

PATENT
Attorney Docket No. 17682A-005100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:)
U.S. Patent No. 5,824,796)
Inventors: Charles R. Petrie, Rich B. Meyer,)
John C. Tabone and Gerald D. Hurst)
Serial No.: Not yet assigned) REISSUE DECLARATION UNDER
File: Herewith) 37 C.F.R. § 1.175(a) AND POWER OF
For: CROSS-LINKING) ATTORNEY
OLIGONUCLEOTIDES)

)

BOX REISSUE APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

We, Charles R. Petrie, Rich B. Meyer, John C. Tabone and Gerald D. Hurst declare as follows:

1. Charles R. Petrie of 18459 NW 196th Place, Woodinville, Washington 98072, Rich B. Meyer of 3739 Hamilton Way, Redwood City, California 94062, John C. Tabone of 12117 NE 166th Place, Bothell Washington 98011 and Gerald D. Hurst of *address unknown*, are citizens of the United States of America.

2. The entire right, title, and interest to U.S. Patent No. 5,824,796, issued October 20, 1998, is vested in Epoch Biosciences, Inc., a Delaware corporation, by assignment. Epoch Biosciences, Inc. has a regular and established place of business in Redmond, Washington 98052. An assignment from us to Microprobe Corporation (now Epoch Biosciences, Inc.) was recorded on October 26, 1988 at Reel 4963, Frame 220 for parent application Serial No. 250,474 and on July 24, 1989 at Reel 5162, Frame 48 for parent application Serial No. 353,857.

3. We are the original, first and joint inventors of the invention described and claimed in the above-identified United States Letters Patent and the claims added by the above referenced reissue application, for which invention we seek a reissue of the aforesaid Letters Patent.

4. We do not know and do not believe that said invention was ever known or used in the United States of America before our invention thereof.

5. We do not know and do not believe that said invention was in public use more than one year prior to filing the original application for U.S. Patent No. 5,824,796.

6. We do not know and do not believe that the invention was on sale, within the meaning of 35 USC 102(b), in this country more than one year prior to the filing date of said original application.

7. We also believe the original patent to be partly or wholly inoperative or invalid because of error without deceptive intent on our part. We believe the original patent to be partly or wholly inoperative or invalid because we claimed less than that to which we had a right to claim in the patent. In particular we believe that it was error not to include those compounds in which the linking groups between the nucleic acid bases and the reporter groups were unsaturated alkyl chains, such as for example, C₂-C₁₂ alkenylene and C₂-C₁₂ alkynylene in the original patent. New claims 16 through 44 are now added as reissue claims. The errors which resulted in this application for reissue and resulted in such claims not being included in the original patent arose due to our failure to appreciate the extent to which the original claims included elements which unduly limited the scope of protection afforded our invention. Our original patent claims, see claims 1-15, for example, contained claims to oligonucleotides and compounds in which crosslinking groups and reporter groups are attached to the oligonucleotide or compound via a saturated alkylene chain that is optionally interrupted by a heteroatom (e.g., O, NH or S). We believe we are also entitled to claims drawn to intermediates in the preparation of the claimed compounds that terminate in a heteroatom or protected form thereof.

8. More specifically, in the original application, we failed to recognize and appreciate features and combinations of the invention which we invented and which we believe are patentable over the prior art. We have added new claims 16-44 to other oligonucleotides and compounds of modified pyrazolo[3,4-d]pyrimidines and other pyrimidine bases to correct our error in not so claiming in our original patent. We believe this occurred in part because our preferred embodiment was the cross-linking oligonucleotides, and we failed to recognize that certain intermediates and other species of labeled compounds and oligonucleotides could be claimed.

9. We have reviewed and understand the contents of the attached specification and claims, including the new claims as presented in this application for reissue of the original Letters Patent.

10. We acknowledge the duty to disclose information of which we are aware and which is material to the examination of this application for reissue of the original Letters Patent in accordance with 37 C.F.R. § 1.56.

11. The aforementioned errors in claiming less than we had a right to claim arose without any deceptive intention on our part and was only recognized as a result of comparing the issued claims with the business interests of Epoch Pharmaceuticals, Inc., now Epoch Biosciences, Inc.

12. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

13. We hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: William M. Smith, Reg. No. 30,223, William B. Kezer, Reg. No. 37,369, Eugenia Garrett-Wackowski, Reg. No. 37,330, Joseph R. Snyder, Reg. No. 39,381 and Kevin L. Bastian, Reg. No. 34,774.

14. Please send all correspondence to Townsend and Townsend and Crew LLP, ATTN: William B. Kezer, Two Embarcadero Center, 8th Floor, San Francisco, California 94111-3834. Direct all telephone calls to Mr. Kezer at (415) 576-0200.

15. This declaration may be executed in counterpart and by copy with the same force and effect as if executed as one complete and integrated document.

Full name of first inventor: Charles R. Petrie

Inventor's signature: 

Date: _____ Country of Citizenship: U.S.A.

Residence: 18459 NW 196th Place, Woodinville, Washington 98072

Full name of second inventor: Rich B. Meyer

Inventor's signature: 

Date: 10/16/00 Country of Citizenship: U.S.A.

Residence: 3739 Hamilton Way, Redwood, California 94062

Full name of third inventor: John C. Tabone

Inventor's signature: _____

Date: _____ Country of Citizenship: U.S.A.

Residence: 12117 NE 166th Place, Bothell Washington 98011

Full name of third inventor: Gerald D. Hurst

Inventor's signature: _____

Date: _____ Country of Citizenship: U.S.A.

Residence: *Unknown*

SF1142663

Express Mail Label No. EL00822715US
Date of Deposit 10/19/00

PATENT
Attorney Docket No. 17682A-005100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:)
U.S. Patent No. 5,824,796)
Inventors: Charles R. Petrie, Rich B. Meyer,)
John C. Tabone and Gerald D. Hurst) REISSUE DECLARATION UNDER
Serial No.: Not yet assigned) 37 C.F.R. § 1.175(a) AND POWER OF
Filed: Herewith) ATTORNEY
For: CROSS-LINKING)
OLIGONUCLEOTIDES)

)

BOX REISSUE APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

We, Charles R. Petrie, Rich B. Meyer, John C. Tabone and Gerald D. Hurst
declare as follows:

1. Charles R. Petrie of 18459 NW 196th Place, Woodinville, Washington
98072, Rich B. Meyer of 3739 Hamilton Way, Redwood City, California 94062, John C. Tabone
of 12117 NE 166th Place, Bothell Washington 98011 and Gerald D. Hurst of *address unknown*,
are citizens of the United States of America.

2. The entire right, title, and interest to U.S. Patent No. 5,824,796, issued
October 20, 1998, is vested in Epoch Biosciences, Inc., a Delaware corporation, by assignment.
Epoch Biosciences, Inc. has a regular and established place of business in Redmond, Washington
98052. An assignment from us to Microprobe Corporation (now Epoch Biosciences, Inc.) was
recorded on October 26, 1988 at Reel 4963, Frame 220 for parent application Serial No. 250,474
and on July 24, 1989 at Reel 5162, Frame 48 for parent application Serial No. 353,857.

3. We are the original, first and joint inventors of the invention described and claimed in the above-identified United States Letters Patent and the claims added by the above referenced reissue application, for which invention we seek a reissue of the aforesaid Letters Patent.

4. We do not know and do not believe that said invention was ever known or used in the United States of America before our invention thereof.

5. We do not know and do not believe that said invention was in public use more than one year prior to filing the original application for U.S. Patent No. 5,824,796.

6. We do not know and do not believe that the invention was on sale, within the meaning of 35 USC 102(b), in this country more than one year prior to the filing date of said original application.

7. We also believe the original patent to be partly or wholly inoperative or invalid because of error without deceptive intent on our part. We believe the original patent to be partly or wholly inoperative or invalid because we claimed less than that to which we had a right to claim in the patent. In particular we believe that it was error not to include those compounds in which the linking groups between the nucleic acid bases and the reporter groups were unsaturated alkyl chains, such as for example, C₂-C₁₂ alkenylene and C₂-C₁₂ alkynylene in the original patent. New claims 16 through 44 are now added as reissue claims. The errors which resulted in this application for reissue and resulted in such claims not being included in the original patent arose due to our failure to appreciate the extent to which the original claims included elements which unduly limited the scope of protection afforded our invention. Our original patent claims, see claims 1-15, for example, contained claims to oligonucleotides and compounds in which crosslinking groups and reporter groups are attached to the oligonucleotide or compound via a saturated alkylene chain that is optionally interrupted by a heteroatom (e.g., O, NH or S). We believe we are also entitled to claims drawn to intermediates in the preparation of the claimed compounds that terminate in a heteroatom or protected form thereof.

8. More specifically, in the original application, we failed to recognize and appreciate features and combinations of the invention which we invented and which we believe are patentable over the prior art. We have added new claims 16-44 to other oligonucleotides and compounds of modified pyrazolo[3,4-d]pyrimidines and other pyrimidine bases to correct our error in not so claiming in our original patent. We believe this occurred in part because our preferred embodiment was the cross-linking oligonucleotides, and we failed to recognize that certain intermediates and other species of labeled compounds and oligonucleotides could be claimed.

9. We have reviewed and understand the contents of the attached specification and claims, including the new claims as presented in this application for reissue of the original Letters Patent.

10. We acknowledge the duty to disclose information of which we are aware and which is material to the examination of this application for reissue of the original Letters Patent in accordance with 37 C.F.R. § 1.56.

11. The aforementioned errors in claiming less than we had a right to claim arose without any deceptive intention on our part and was only recognized as a result of comparing the issued claims with the business interests of Epoch Pharmaceuticals, Inc., now Epoch Biosciences, Inc.

12. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

13. We hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: William M. Smith, Reg. No. 30,223, William B. Kezer, Reg. No. 37,369, Eugenia Garrett-Wackowski, Reg. No. 37,330, Joseph R. Snyder, Reg. No. 39,381 and Kevin L. Bastian, Reg. No. 34,774.

14. Please send all correspondence to Townsend and Townsend and Crew LLP, ATTN: William B. Kezer, Two Embarcadero Center, 8th Floor, San Francisco, California 94111-3834. Direct all telephone calls to Mr. Kezer at (415) 576-0200.

15. This declaration may be executed in counterpart and by copy with the same force and effect as if executed as one complete and integrated document.

Full name of first inventor: Charles R. Petrie

Inventor's signature: _____

Date: _____ Country of Citizenship: U.S.A.

Residence: 18459 NW 196th Place, Woodinville, Washington 98072

Full name of second inventor: Rich B. Meyer

Inventor's signature: _____

Date: _____ Country of Citizenship: U.S.A.

Residence: 3739 Hamilton Way, Redwood, California 94062

Full name of third inventor: John C. Tabone

Inventor's signature: John C. Tabone

Date: 10/17/00 Country of Citizenship: U.S.A.

Residence: 12117 NE 166th Place, Bothell Washington 98011

Full name of third inventor: Gerald D. Hurst

Inventor's signature: _____

Date: _____ Country of Citizenship: U.S.A.

Residence: *Unknown*

SF1142663